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A B S T R A C T
Background
Tobacco use is highly prevalent amongst people living with HIV/AIDS (PLWHA) and has a substantial impact on morbidity and
mortality.
Objectives
To assess the effectiveness of interventions to motivate and assist tobacco use cessation for people living with HIV/AIDS (PLWHA),
and to evaluate the risks of any harms associated with those interventions.
Search methods
We searched the Cochrane Tobacco Addiction Group’s Specialised Register, Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, EMBASE, and PsycINFO in June 2015. We also searched EThOS, ProQuest, four clinical trial registries, reference
lists of articles, and searched for conference abstracts using Web of Science and handsearched speciality conference databases.
Selection criteria
Controlled trials of behavioural or pharmacological interventions for tobacco cessation for PLWHA.
Data collection and analysis
Two review authors independently extracted all data using a standardised electronic data collection form. They extracted data on the
nature of the intervention, participants, and proportion achieving abstinence and they contacted study authors to obtain missing
information. We collected data on long-term (greater than or equal to six months) and short-term (less than six months) outcomes.
Where appropriate, we performed meta-analysis and estimated the pooled effects using the Mantel-Haenszel ﬁxed-effect method. Two
authors independently assessed and reported the risk of bias according to prespeciﬁed criteria.
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Main results
We identiﬁed 14 studies relevant to this review, of which we included 12 in a meta-analysis (n = 2087). All studies provided an
intervention combining behavioural support and pharmacotherapy, and in most studies this was compared to a less intensive control,
typically comprising a brief behavioural intervention plus pharmacotherapy.
There was moderate quality evidence from six studies for the long-term abstinence outcome, which showed no evidence of effect for
more intense cessation interventions: (risk ratio (RR) 1.00, 95% conﬁdence interval (CI) 0.72 to 1.39) with no evidence of heterogeneity
(I2 = 0%). The pooled long-term abstinence was 8% in both intervention and control conditions. There was very low quality evidence
from 11 studies that more intense tobacco cessation interventions were effective in achieving short-term abstinence (RR 1.51, 95%
CI 1.15 to 2.00); there was moderate heterogeneity (I2 = 42%). Abstinence in the control group at short-term follow-up was 8% (n =
67/848) and in the intervention group was 13% (n = 118/937). The effect of tailoring the intervention for PLWHA was unclear. We
further investigated the effect of intensity of behavioural intervention via number of sessions and total duration of contact. We failed
to detect evidence of a difference in effect according to either measure of intensity, although there were few studies in each subgroup.
It was not possible to perform the planned analysis of adverse events or HIV outcomes since these were not reported in more than one
study.
Authors’ conclusions
There is moderate quality evidence that combined tobacco cessation interventions provide similar outcomes to controls in PLWHA
in the long-term. There is very low quality evidence that combined tobacco cessation interventions were effective in helping PLWHA
achieve short-term abstinence. Despite this, tobacco cessation interventions should be offered to PLWHA, since even non-sustained
periods of abstinence have proven beneﬁts. Further large, well designed studies of cessation interventions for PLWHA are needed.
P L A I N L A N G U A G E S U M M A R Y
Interventions to help people living with HIV and AIDS to stop using tobacco
Background: Tobacco use is common amongst people living with HIV and AIDS (PLWHA); it causes a range of health problems
and accounts for many deaths. There is good evidence about interventions to help people quit tobacco use in the general population,
however the effectiveness in PLWHA was not known.
Methods: We reviewed the available evidence from trials to help PLWHA stop using tobacco. This evidence is correct up to June 2015.
We conducted analyses of whether people were able to successfully quit tobacco use in the long-term (six months and over) and short-
term (measured at less than six months).
Results: We found 14 relevant studies including over 2000 participants. All studies, except one, were conducted in the United States
(US). All studies compared a behavioural intervention with medication, to a control group. The behavioural intervention was delivered
via a range of methods including face-to-face, telephones, computers, and text messages. Nicotine replacement therapy or varenicline
(medications that help tobacco users quit) was also given. Control participants typically received a less intensive, brief behavioural
intervention, and the same medication as the intervention group. Six studies of moderate quality evidence investigated long-term
abstinence; they did not show clear evidence of beneﬁt of the more intense intervention. Eleven studies of very low quality evidence
investigated short-term abstinence. The evidence suggested that a more intense intervention combining behavioural support and
medication might help people to quit in the short-term.
Quality of the evidence: The quality of the evidence was judged to be moderate for the long-term abstinence outcome and very low
for the short-term abstinence outcome, and so further research is needed to increase our conﬁdence in our ﬁndings.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tobacco use cessation in people living with HIV and AIDS
Patient or population: consumers of tobacco living with HIV and AIDS
Setting: All included studies conducted in USA
Intervention: combined pharmacotherapy and behavioural support for smoking cessat ion
Comparison: control
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control Risk with combined
cessation intervention
Proport ion of part ici-
pants abst inent - long-
term (> 6 months)
assessed via self report
+/ - biochemical verif i-
cat ion
Study populat ion RR 1.00
(0.72 to 1.39)
1602
(6 RCTs)
⊕⊕⊕©
MODERATE 1
80 per 1000 80 per 1000
(58 to 112)
Moderate
63 per 1000 63 per 1000
(46 to 88)
Proport ion of part ici-
pants abst inent - short-
term (> 4 weeks to < 6
months)
assessed via self report
+/ - biochemical verif i-
cat ion
Study populat ion RR 1.51
(1.15 to 2.00)
1785
(11 RCTs)
⊕©©©
VERY LOW 1,2,3
79 per 1000 119 per 1000
(91 to 158)
Moderate
65 per 1000 98 per 1000
(75 to 130)
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to risk of bias. One study had high risk of report ing bias (although impact on results mit igated by obtaining
unpublished data f rom study authors). Allocat ion concealment and blinding poorly described.
2 Downgraded due to suspected publicat ion bias indicated by asymmetrical funnel plot.
3 Downgraded due to inconsistency. The direct ion of ef fect was not always consistent and moderate heterogeneity was
present (I2 = 42%).
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B A C K G R O U N D
The introduction of combination anti-retroviral therapy (ART)
has transformed HIV into a chronic disease (Deeks 2013), com-
parable to other long-term conditions such as diabetes (Nakagawa
2012). Once diagnosed, people living with HIV/AIDS (PLWHA)
can have a near normal life expectancy (Nakagawa 2012). Causes
of morbidity and mortality have changed; between 50% and 84%
of deaths in PLWHA are now not AIDS-related (Ehren 2014;May
2013; Weber 2013), and rates of opportunistic infections have
declined substantially over the past two decades (Buchacz 2010).
Non-communicable diseases, particularly ischaemic heart disease
and lung cancer, now represent a growing burden of disease in this
population (May 2013).
The prevalence of tobacco consumption in PLWHA is substantial,
and greater than that of the general population: between 47% and
65% of PLWHA smoke cigarettes (Friis-Møller 2003; Helleberg
2013; Miguez-Burbano 2005). Prevalence of tobacco use varies
between countries, but there is evidence that PLWHA consume
more tobacco than the general population in a range of contexts,
from Zimbabwe to the United States (US) (Gritz 2004; Munyati
2006). Where ART is accessible, smoking results in greater loss
of life years than the HIV infection itself in PLWHA who smoke
(Helleberg 2013). In light of the high prevalence of smoking in
combination with the changing trends inmorbidity andmortality,
smoking cessation has become highly relevant for this population.
Description of the condition
Tobacco may affect the immune system of PLWHA, resulting
in increased viral replication in macrophages, microglial, and T
cells (Abbud 1995, Valiathan 2014). Valiathan and colleagues
demonstrated that PLWHA who smoked had higher levels of im-
mune exhaustion and impaired T cell functioning compared to
both PLWHAnon-smokers andHIV-negative smokers (Valiathan
2014).
Untreated HIV destroys CD4 cells (T4 lymphocytes expressing
CD4 proteins), which play a central role in the immune system
(Naif 2013; Simon 2006). In untreated HIV infection the ’CD4
count’ (number of CD4 cells) gradually falls, increasing the risk
of opportunistic infections and other complications (Naif 2013;
Simon 2006). Treatment with ART aims to increase the CD4
count and to achieve viral suppression - to reduce the amount of
HIV virus in the blood (the ‘viral load’) to an undetectable level.
Smoking tobacco may affect the immune response to ART. Some
evidence indicates that tobaccousemight be associatedwith poorer
ART outcomes including a lower likelihood of achieving viral sup-
pression, and a higher likelihood of immunological failure (when
CD4 count falls below the lowest point it had been prior to ART
initiation) (Feldman 2006). However, cohort study data showed
no difference in CD4 and viral load between smokers and non-
smokers (Helleberg 2015).
Tobacco use causes substantial morbidity and mortality in
PLWHA. The tobacco-related harm is substantially higher in
PLWHA than smokers in the general population. Smoking was
found to be attributable for 24.3% of all-cause mortality, 25.3% of
major cardiovascular disease, 30.6% of non-AIDS-related cancer,
and 25.4% of bacterial pneumonia amongst people living with
HIV (Lifson 2010). This is partly due to a higher prevalence of to-
bacco use in PLWHA than the general population and partly due
to their increased susceptibility to the impact of tobacco compared
to other smokers. Lung cancer is the commonest non-AIDS-re-
lated cancer amongst PLWHA (May 2013), and compared to the
general population, lung cancer occurs at a younger age and af-
ter shorter exposure to cigarettes (Winstone 2013). HIV has been
identiﬁed as an independent factor for greater lung cancer risk
(Sigel 2012). In addition, smoking is associated with increased in-
cidence of a number of other cancers in PLWHA, including cancer
of the anus and mouth (Bertisch 2013; Clifford 2005). Cardio-
vascular disease risk may be elevated in PLWHA, due to a combi-
nation of HIV viraemia, a pro-inﬂammatory state, and the associ-
ation of some ART regimens with high cholesterol and impaired
glucose tolerance (Friis-Møller 2003; Palella 2011). Tobacco use
further increases cardiovascular risk, and cessation was found to
be effective in signiﬁcantly reducing this risk (Petoumenos 2011).
Case-control studies show that the impact of smoking on acute
coronary syndrome is nearly doubled for PLWHA who smoked
compared to HIV-negative controls (Calvo-Sánchez 2013).
Amongst PLWHAwho consume tobacco, incidence of oral lesions
such as oral candidiasis and oral hairy leukoplakia are increased
compared to non-users (Sroussi 2007). Current smokers are at sig-
niﬁcantly higher risk of bacterial pneumonia than non-smokers
(Gordin 2008). The outcome of chronic obstructive pulmonary
disease may be worse in PLWHA compared to HIV-negative peo-
ple (Morris 2011). Smoking tobacco during pregnancy is an inde-
pendent risk factor for adverse pregnancy outcomes for PLWHA,
including small for gestational age, low birth weight and preterm
birth (Aliyu 2013).
PLWHA who use tobacco are different from other tobacco users
in several respects, which justiﬁes a focused evidence review for
smoking cessation in this population. PLWHA have been shown
to have higher nicotine dependency levels than the general popula-
tion and there is an increased prevalence of other co-dependencies,
such as alcohol and illicit drugs (Benard 2007). This makes them
more vulnerable towithdrawal symptomson stopping tobaccouse,
and means sustained abstinence could be difﬁcult to achieve. The
prevalence of mental illness, particularly depression, in PLWHA
is higher than that in the general population (Nurutdinova 2012;
Schadé 2013), and is associated with a lower likelihood of quit-
ting smoking and an increased likelihood of relapse after quit-
ting (Weinberger 2012). Tobacco use was reported as a coping
mechanism for general HIV-related symptoms and speciﬁcally for
HIV-related neuropathy, depression, anxiety, and ART-associated
lipodystrophy (Grover 2013; Reynolds 2004; Shuter 2012a). De-
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spite the good prognosis of HIV, some PLWHA report fatalistic
ideas and a pessimistic perception of their life expectancy, affect-
ing their perceived susceptibility-associated risks of tobacco; one
participant said: “If I live long enough to get cancer that’s great!”
(Reynolds 2004).
Socioeconomic factors also have a substantial impact on tobacco
use. Many PLWHA who use tobacco are members of one or more
marginalised groups, including ethnic minorities, migrants, and
men who have sex with men. Tobacco use was found to be con-
sistently higher in lesbian, gay, bisexual, and transgender adults,
compared to heterosexual adults in a range of countries (Marshal
2008), and they are also at higher risk of HIV. Additionally, in
one study of PLWHA who use tobacco, two-thirds were found to
be unemployed, almost half had an income under USD 10,000
per annum and more than one-third were in inadequate housing
(Humﬂeet 2009). These factors may contribute to their continued
tobacco use and reduce the likelihood of success in quitting. So-
cial support networks are lacking for many PLWHA. In addition,
some PLWHA who smoke, report that more than 40% of people
in their social network are smokers, reinforcing their continued
smoking (Humﬂeet 2009).
Description of the intervention
In the general population, combined pharmacotherapy and coun-
selling interventions are effective in achieving tobacco cessation
(Stead 2016). PLWHA who are engaged in care, come into fre-
quent contact with health professionals for regular tests and clinic
appointments. This presents an opportunity to discuss and sup-
port cessation, but currently this opportunity is underutilised.
HIV clinicians report a lack of conﬁdence in initiating cessation
therapies and insufﬁcient time, despite recognising the impor-
tance (Horvath 2012; Shuter 2012b). Despite previous unsuccess-
ful attempts to quit by over 80% of PLWHA who smoke (Shuter
2012a), a high proportion remainmotivated to quit (Benard 2007;
Shuter 2012a). The high prevalence of smoking, despite a substan-
tial proportion expressing a desire to quit, reﬂects an unmet need
for effective tobacco cessation interventions in PLWHA. There is
need for clarity in how best to support PLWHA in tobacco cessa-
tion.
Tobacco cessation interventions may be brief advice, behavioural,
pharmacological, or a combination. Behavioural support inter-
ventions may include group or individual counselling, consisting
of appointments following the quit attempt where the smokers
receive information, advice, and encouragement. Pharmacologi-
cal interventions may include use of nicotine replacement therapy
(NRT) via a range of modalities, as well as bupropion or vareni-
cline. The literature on tobacco cessation suggests that individual
pharmacotherapies are effective for tobacco cessation; however,
these in combination with behavioural support are found to be
more effective in the general population (Stead 2016). There is
evidence of effectiveness of these tobacco cessation interventions
in the general population (Stead 2012; Stead 2016), but to our
knowledge, there has not been an in-depth systematic review into
their effectiveness in PLWHA.
Why it is important to do this review
Tobacco use is highly prevalent and responsible for substantial
morbidity and mortality amongst PLWHA (Helleberg 2013). It
is therefore, important that health workers have the best available
evidence to support PLWHA in their attempts to quit tobacco.
A dedicated review of cessation interventions in PLWHA is justi-
ﬁed as a number of relevant attributes of tobacco users with HIV/
AIDS differ from those of other tobacco users. Furthermore, de-
spite motivation to quit, PLWHA often ﬁnd it difﬁcult to achieve
sustained abstinence.
O B J E C T I V E S
Primary objective:
1. To assess the effectiveness of interventions to motivate and
assist tobacco use cessation for people living with HIV/AIDS
(PLWHA), and to evaluate the risks of any harms associated with
those interventions.
Secondary objectives:
1. To assess whether interventions combining
pharmacotherapy and behavioural support are more effective
than either type of support alone in PLWHA.
2. To assess whether in PLWHA, tobacco cessation or
cessation induction interventions tailored to PLWHA are more
effective than ‘usual care’ non-tailored cessation interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Randomised controlled trials (RCTs).
2. Cluster-randomised controlled trials (cluster-RCTs).
3. Quasi-randomised controlled trials.
4. Other non-randomised controlled trials.
We did not exclude studies on the basis of language or publication
status.
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Types of participants
We included trials of adults over 18 years who were HIV-positive.
We included studies of all stages of HIV infection, and studies of
men only, women only, and all genders.
Trial participantswere consumers of tobacco.Hadwe located stud-
ies which differentiated between different types of tobacco users,
we would have considered subgroup analysis.
Types of interventions
We included interventions that targeted individuals. The inter-
ventions included behavioural and pharmacological elements. We
did not locate any studies of cessation induction trials (typically
brief advice by health professionals) that aimed to encourage fu-
ture quit attempts by those tobacco users who were unwilling to
give up at the time of recruitment.
We included interventions delivered via any format including tele-
phone call, the Internet, and face-to-face. There was no restriction
on the identity of the provider which included nurses, counsellors,
and peers.
Types of outcome measures
Primary outcomes
The primary outcome measure is tobacco abstinence at a mini-
mum of six months after the start of the intervention, referred to
as long-term cessation. We did include trials with a shorter fol-
low-up, but these did not contribute to the primary analysis. We
recognise that measurement of cessation at six months or longer
is optimal (West 2005); however we included a shorter-term out-
come measure due to the relative paucity of research in the area of
tobacco cessation for PLWHA.We assessed short-term abstinence
as a secondary outcome measure and completed separate analyses
for the short- and long-term follow-up periods.
We used the strictest deﬁnition of abstinence reported in the study,
using sustained abstinence rates in preference to point prevalence,
or ﬂoating prolonged abstinence. Deﬁnitions of sustained absti-
nence may allow for a small number of cigarettes during the pe-
riod (West 2005). We preferred, but did not require, that absti-
nence was biochemically veriﬁed (for example, by exhaled car-
bon monoxide or serum, salivary, or urinary cotinine). We treated
those participants lost to follow-up as continuing users of tobacco.
These outcome measures are guided by the Russell Standards for
smoking cessation trials (West 2005).
Secondary outcomes
We assessed short-term abstinence as a secondary outcome mea-
sure.We required that the assessment point was at least four weeks,
but less than six months, from the target quit date, or start of the
intervention for studies of cessation induction.
In addition to short-term abstinence, we planned to look for data
on the following secondary outcome measures: HIV viral load,
CD4 count, and the incidence of opportunistic infections. We
planned to extract data on and report any adverse effects.
Search methods for identiﬁcation of studies
Electronic searches
The Tobacco Addiction Group’s Trials Search Co-ordinator
searched the Cochrane Tobacco Addiction Group’s Specialised
Register using terms related to the topic of HIV/AIDS, and
the Cochrane Central Register of Controlled Trials (CENTRAL)
combining topic-related and smoking cessation terms. We also
searchedMEDLINE, EMBASE, and PsycINFO, combining HIV
topic terms with the smoking-related terms and study design lim-
its, as used for the Specialised Register. The MEDLINE search
terms are included in Appendix 1. All searches were carried out on
the 17th June 2015. Not other time period limitations were used.
Searching other resources
We searched the grey literature as follows: theses and dissertations
via EThOS and ProQuest. We looked for conference abstracts by
searching the Conference Proceedings database in Web of Science
and by handsearching the databases of the Society for Research
on Nicotine and Tobacco, International AIDS Conference, and
British HIV Association. We reviewed reference lists of literature
reviews and consulted experts via email.
We searched for clinical trials via the US National Institutes
of Health registry at www.clinicaltrials.gov, the World Health
Organization (WHO) trials registry platform at apps.who.int/
trialsearch/, the European Union (EU) clinical trials register at
www.clinicaltrialsregister.eu, and the Pan African Clinical Trials
Registry at www.pactr.org. For unpublished trials identiﬁed via
the registries, we attempted to contact authors and requested data
for analysis.
Data collection and analysis
Selection of studies
Two review authors (EP reviewed all studies, RL and KS each re-
viewed a proportion) independently checked the title and abstracts
of all retrieved records for relevance. Two authors (from EP, KS,
and RL) then each reviewed the full-text reports of all studies not
excluded based on title or abstract, and which were potentially
eligible for inclusion. We resolved any disagreements regarding
study inclusion through discussion with a third party (OD). We
recorded the selection process in sufﬁcient detail to complete a
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PRISMA ﬂow diagram (Moher 2009), and ’Characteristics of ex-
cluded studies’ table.
Data extraction and management
Two review authors (from EP, OD, and RL) extracted data using a
standardised electronic data collection form.We then entered data
intoReviewManager 5 computer software for preparingCochrane
systematic reviews (RevMan 2014).
We extracted the following information, where available, for each
study, in the Characteristics of included studies tables.
1. Methods: Study name (if applicable), study recruitment
period, country, number of study centres, study setting, study
recruitment procedure, study design.
2. Participants: N (intervention/control), deﬁnition of smoker
used, speciﬁc demographic characteristics (e.g. mean age, age
range, gender, ethnicity, sexuality), mean cigarettes per day, mean
Fagerström Test for Nicotine Dependence (FTND) score,
relevant inclusion criteria and exclusion criteria.
3. Interventions: Description of intervention(s) (treatment,
dosage, regimen, behavioural support), description of control
(treatment, dosage, regimen, behavioural support); what
comparisons will be constructed between which groups,
concomitant medications, and excluded medications.
4. Outcomes: Abstinence time points for long- and short-term
analyses, deﬁnition of abstinence (e.g. sustained or point
prevalence) at each point, biochemical validation, proportion of
participants with follow-up data at each point. Other outcome
reported (HIV viral load, CD4 count, incidence of opportunistic
infections, adverse effects).
5. Notes: Source of funding for trial, and notable conﬂicts of
interest of trial authors.
Assessment of risk of bias in included studies
As recommended in Chapter 8 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions, we utilised the ’Risk of bias’ tool
within Review Manager 5 to assess the risk of bias for each in-
cluded study (Higgins 2011; RevMan 2014). Two review authors
(from EP, OD, and RL) independently assessed and reported the
following information in the ’Risk of bias’ table.
1. Method of random sequence generation.
2. Method of allocation concealment.
3. Blinding of participants, providers, or outcome assessors.
4. Numbers lost to follow-up or with unknown outcome, for
each outcome used in the review, by intervention/control group.
5. Selective outcome reporting.
6. Any other threats to study quality.
We graded each trial as being at ’high’, ’low’, or ’unclear’ risk of
bias for each domain, and provided justiﬁcation for our judgement
in the table. We summarised the risk of bias judgements across
different studies for each of the domains listed, and displayed the
summary results in two ’Risk of bias’ ﬁgures.
Measures of treatment effect
We calculated a risk ratio (RR) for each cessation outcome for
each trial included in the meta-analysis as follows: (number of
participants abstinent from tobacco in the intervention group/
number of participants in the intervention group) / (number of
participants abstinent from tobacco in the control group/number
of participants in the control group).
Unit of analysis issues
The unit of analysis is the individual level.
Dealing with missing data
Where we identiﬁed missing data, we contacted the study authors
to request missing data. We also contacted study authors if aspects
of trial design or conduct were unclear.
We treated participants who have dropped out, or who were lost to
follow-up, as continuing to use tobacco. We completed reanalysis,
where possible, if study authors had not considered these partic-
ipants as continuing to use tobacco. We noted the proportion of
participants for whom data were missing in the ’Risk of bias’ table.
Assessment of heterogeneity
We evaluated levels of heterogeneity (study characteristics, meth-
ods, outcomes) between included studies to decide whether or not
it is appropriate to pool the data, in two ways; ﬁrstly by checking
if the conﬁdence intervals (CIs) overlap. We used the I² statistic
to assess statistical heterogeneity, given by the formula [(Q - df )/
Q] x 100%, where Q is the Chi² statistic and df is its degrees
of freedom (Higgins 2003). This describes the percentage of the
variability in effect estimates that is due to heterogeneity rather
than to sampling error (chance). A value greater than 50%may be
considered to indicate substantial heterogeneity. The test has low
power when used on a small number of studies (Higgins 2011).
Assessment of reporting biases
Searching multiple sources (as detailed in the search strategies
above) should reduce reporting biases. We avoided language bias
by not limiting the search terms by language and used translation
services where required. We did not exclude on the basis of publi-
cation status and aimed to minimise publication bias by inclusion
of grey literature, conference abstracts, and the inclusion of data
from unpublished trials identiﬁed from trial registries (Higgins
2011). However, this is dependent on the data being obtained.
We created a funnel plot with pseudo-95% conﬁdence limits to
identify possible publication bias for the secondary outcome of
short-term cessation. We did not create a funnel plot for the pri-
mary outcome (long-term cessation) because we identiﬁed less
than ten studies.
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Data synthesis
We extracted data from individual studies, reported them in ta-
ble form, and completed a meta-analysis. We calculated quit rates
based onnumbers randomised to an intervention or control group.
Where possible, we conducted intention-to-treat analyses, i.e. in-
cluding all participants initially assigned to intervention or control
in their original groups. We excluded from the denominators any
deaths. We treated any other losses to follow-up as continuing to-
bacco users, as described above. We noted adverse events, serious
adverse events, and deaths in the Results section.
Incidence of adverse events were poorly reported. It was therefore
not possible to conduct a meta-analysis of the incidence of serious
adverse events, taking those randomised as the denominator and
including events up to thirty days after the end of treatment. It
was also not possible to conduct a sensitivity analyses restricting
the denominator to those known to have taken at least one dose
of treatment/intervention as this ﬁgure was not reported.
For the meta-analysis, we pooled RRs using a Mantel-Haenszel
ﬁxed-effect model ((number of events in intervention condition/
intervention denominator) / (number of events in control condi-
tion/control denominator)) with a 95% CI. Where the event is
deﬁned as tobacco cessation, a RR greater than one indicates that
more people successfully quit in the treatment group than in the
control group.
’Summary of ﬁndings’ table
We created a ’Summary of ﬁndings’ table for long-term abstinence
outcomes (sixmonths or longer) and short-term outcomes (greater
than or equal to four weeks, but less than six months). We used
the ﬁve GRADE considerations (study limitations, consistency of
effect, imprecision, indirectness, and publication bias) to assess the
quality of the body of evidence as it relates to the studies which
contribute data to the prespeciﬁed outcomes. We used methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), using GRADEpro software (GRADEproGDT
2015). We justiﬁed all decisions to down- or upgrade the quality
of the evidence using footnotes.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses, to explore the impact of dif-
ferent variables on the ﬁndings of the review. This allowed us to
identify and investigate unexplained sources of heterogeneity.
We also completed subgroup analyses to compare the relative ef-
ﬁcacy of the different interventions. We were unable to complete
subgroup analysis to establish the effect of combined behavioural
and pharmacological interventions versus single-focus interven-
tions in PLWHA since all identiﬁed studies used combination in-
terventions. We therefore added a post hoc objective to investigate
the effect of intensity of the intervention.
We conducted additional subgroup analyses for each intervention-
population-outcome association and study characteristics to ex-
plore sources of any heterogeneity, using the I² statistic.
Only one study reported on the outcomes of HIV viral load and
CD4 count. therefore. we did not calculate the RR or mean dif-
ference (MD).
We conducted subgroup analyses based on the provider of the
behavioural intervention, mode of contact, participant selection,
tailoring, number of sessions, and total duration of contact. The
subgroups are as follows.
Provider of behavioural intervention
• Healthcare professional
• Researcher
• Co-facilitation by a PLWHA peer and a health professional
Mode of contact
• Face-to-face
• Telephone
• Text message
• Website/computer-based
Where the intervention was undertaken via more than one mode,
the most frequently used mode was coded.
Participant selection
• Selected for willingness or motivation to quit
• Not selected for willingness or motivation to quit
Tailoring
• Intervention tailored for PLWHA
• Intervention not tailored for PLWHA
Where no tailoring was described, it was assumed that the inter-
vention was non-tailored.
Intensity
A post hoc objective involved analysis according to intensity of
behavioural intervention. This analysis was undertaken using the
same categories deﬁned in a previous Cochrane review (Stead
2016), adapted from the US Guidelines AHRQ 2008. This in-
volved analysis according to number of sessions and total duration
of contact time. We used planned contact time and number of
sessions where possible, if this was not reported or not clear, we
used the reported average.
We categorised total contact time as follows.
• 0 (where support was provided by text message or website
use alone)
• 1 to 30 minutes
• 31 to 90 minutes
• 91 to 300 minutes
• More than 300 minutes
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We categorised number of person-to-person sessions as follows.
• 0 (where support was provided by text message or website
use alone)
• 1 - 3 sessions
• 4 - 8 sessions
• More than 8 sessions
Intensity subgroup analyses were not completed for short-term
outcomes because the planned contact may not have been com-
pleted at the time of short-term outcome assessment.
Sensitivity analysis
We tested for small-study effects on the results of themeta-analysis
performed.
R E S U L T S
Description of studies
Results of the search
Figure 1 contains a ﬂow diagram detailing the search results. We
identiﬁed 881 potentially relevant records; we identiﬁed some
studies from more than one record. After screening and duplicate
removal, we assessed 48 studiesfor eligibility and included 14 in
the qualitative synthesis, 12 of which we included in a meta-analy-
sis. The 22 studies that we excluded are listed in Characteristics of
excluded studies, and we judged 12 studies to be ongoing, which
are summarised in Characteristics of ongoing studies. We assigned
the studies a study identiﬁer (ID) based on the ﬁrst author and
year of the ﬁrst major publication.
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Figure 1. Study ﬂow diagram.
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Included studies
Fourteen studies met the inclusion criteria and contributed to the
review.We included all 14 studies in the qualitative synthesis, while
12 studies contributed to the quantitative synthesis. Six studies
contributed to the analysis of long-term tobacco abstinence (the
primary outcome) and 11 studies to short-term abstinence (the
secondary outcome). Four studies reported both long- and short-
term abstinence and we included them in both analyses.
The studies are described in detail in the Characteristics of
included studies table. All studies were conducted after 2000, 13
of the 14 studies were conducted in the US, while one study, Elzi
2006, was conducted in Switzerland. All studies combined a be-
havioural intervention with pharmacotherapy, therefore, we could
not investigate the objective of single versus combined interven-
tion in this review. As an alternative, we investigated the effect of
level of intensity of counselling.
We included two three-arm studies (Humﬂeet 2013; Shelley
2015). In both cases, the two intervention groups were not similar
enough to warrant combining them to create a single group. For
these two studies, we divided the control groupsinto two equal
groups and made independent comparisons as follows: interven-
tion one versus half of the control and intervention two versus
half of the control. For Humﬂeet 2013: computer-based inter-
vention versus control and individual counselling versus control.
For Shelley 2015: text message versus control and text message +
adherence-based therapy versus control. In the meta-analyes, the
intervention groups are identiﬁed in the footnotes.
We did not include two studies in the meta-analysis (Elzi 2006;
Ferketich 2013). Elzi 2006 was nested in the Swiss HIV Cohort
Study (SHCS), the intervention group was not randomised, and
it comprised participants who expressed an interest in quitting.
Whereas, the control group was formed of all other smokers par-
ticipating in the SHCS at the study site; they were therefore sys-
tematically different from the intervention group. Inclusion of
this study in the meta-analysis resulted in substantial heterogene-
ity with an I2 > 80%. We did not include Ferketich 2013 in the
meta-analysis as this study compared two pharmacotherapies and
was not in-keeping with the comparison of behavioural interven-
tion versus less intense behavioural intervention, and did not have
a control arm. The study compared 12 weeks counselling and
varenicline, with 12 weeks counselling and nicotine replacement
therapy (NRT). It was also non-randomised.
Sample size was variable with a high proportion of small stud-
ies; seven studies had a sample size of less than 150 participants
(Cropsey 2013; Ingersoll 2009; Manuel 2013; Moadel 2012;
Shuter 2014; Vidrine 2006; Wewers 2000).
Participant characteristics
More than 1600 participants contributed to the meta-analysis
for the primary outcome of long-term abstinence (six months
or greater). An additional 485 participants contributed to the
meta-analysis for the secondary outcome of short-term abstinence
(greater than or equal to four weeks, but less than six months).
Sexual orientation and ethnicity were recorded inconsistently in
different studies. Only six out of 14 studies reporting any measure
of sexual orientation, despite the relevance of sexual orientation
in studies of PLWHA. Where sexual orientation was described,
approximately 35% to 50% of participants were homosexual. The
overall proportion of homosexual participants ranged from 3% in
Manuel 2013 to 68% inHumﬂeet 2013. Notably, the participants
in Manuel 2013 were all women.
Black or African American ethnicity was the modal category in
eight studies. There were variations: from 95% of participants be-
ing Black in Ingersoll 2009 to 53% White in Humﬂeet 2013.
The population of the only European study was 87%White (Elzi
2006). One study was speciﬁcally designed for the Latino com-
munity, and having a Latino/Hispanic ethnicity was an inclusion
criterion of that study (Stanton 2015). The reported average age
of study participants was approximately 35 to 50 years.
Description of the intervention: behavioural
Provider
Some degree of behavioural intervention was provided to the in-
tervention group in all studies. We categorised the provider of the
behavioural interventions as follows; healthcare professionals, re-
searchers or co-facilitated by a peer and a professional. The in-
tervention was provided by healthcare professionals in nine stud-
ies (Elzi 2006; Ferketich 2013; Humﬂeet 2013; Ingersoll 2009;
Lloyd-Richardson 2009; Manuel 2013; Shelley 2015; Stanton
2015; Vidrine 2012), by a researcher or a graduate student in
two studies (Cropsey 2013; Vidrine 2006), and co-facilitated by
a PLWHA ex-smoker peer alongside a professional in two studies
(Moadel 2012; Wewers 2000).
There was variation in the degree of detail to which the qualiﬁca-
tions or experience of the individuals delivering the behavioural
interventions was described. We therefore adopted a broad cate-
gorisation of ’healthcare professional’, which included nurses, mo-
tivational interviewing clinicians, counsellors, psychologists, and
health educators, irrespective of the detail provided on their coun-
selling skills, experience, or qualiﬁcations. Likewise, while some
studies described the academic qualiﬁcations of the researchers
providing interventions, little detail was provided on their training
or counselling experience.
12Interventions for tobacco use cessation in people living with HIV and AIDS (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
In addition to the website intervention, the participants in the
computer-based intervention group of Humﬂeet 2013 also re-
ceived a 45-60 minute face-to-face meeting, including discussion
of a quit date. However, it is unclear if the provider was a clinician
or a researcher, so this group was not included in the provider
subgroup analysis. We attempted to contact the authors but were
unable to clarify the intervention provider.
Mode of contact
In most studies the behavioural intervention was delivered face-
to-face or via telephone, often in combination. Two studies in-
vestigated computer- or web-based delivery, in which participants
completed online modules (Humﬂeet 2013; Shuter 2014). One
study delivered the intervention entirely via text message (Shelley
2015). Additional resources were provided in most studies, such
as written materials.
Nearly half of the intervention groups (n = 7/16, 44%) offered be-
tween four and eight face-to-face or telephone sessions, and a quar-
ter (n = 4/16, 25%) offered more than eight (Elzi 2006; Ferketich
2013; Vidrine 2012;Wewers 2000).Most of the studies with long-
term follow-up planned to provide 91-300 minutes of total con-
tact time. Categorisations were made according to planned dura-
tion of contact; actual contact time per participant may have been
lower. These categories also do not account for time spent using
web-based interventions or reviewing text messages.
Tailoring
Eleven of the interventions were speciﬁcally tailored to PLWHA.
This was achieved through a range of methods, including empha-
sising impact of tobacco on the immune system and facilitation
by a HIV-positive ex-smoker peer. Some authors did not describe
how the intervention was tailored in detail. In the text message
group of Shelley 2015, the text messages did not contain the words
HIV or AIDS in order to ensure conﬁdentiality, although the
messages were designed to emphasise particular barriers faced by
PLWHA, such as stress.We did consider this intervention tailored,
but recognise that the degree of tailoring varies between studies.
In the computer-based intervention in Humﬂeet 2013, the au-
thors did not explicitly state that the computer-based intervention
was tailored, although it was described as modelled on the indi-
vidual counselling intervention. The counselling intervention was
targeted to the needs of HIV-positive smokers through focussing
on the impact of smoking on HIV. We considered the computer-
based intervention group likely to be tailored, and therefore in-
cluded it in the tailored versus generic control subgroup.
Description of interventions: pharmacotherapy
Nicotine replacement therapy (NRT) via patches and/or lozenges
was offered or provided to the intervention groups inmost studies.
In Shelley 2015 and Ferketich 2013, varenicline was used instead.
No studies included bupropion in their protocol, possibly due to
the potential drug-drug interactions with a number of anti-retro-
viral therapy (ART) drugs. In Shuter 2014 only NRT administra-
tion was planned in the protocol, but some participants also re-
ceived bupropion and varenicline off protocol, however, they were
retained within their original groups for the ITT analysis.
Description of controls
In most studies the control group received ‘usual care’, which typi-
cally comprised NRT or varenicline, brief advice, and written ma-
terials. In two studies, the participants in the control group re-
ceived no behavioural input or pharmacotherapy (Cropsey 2013;
Elzi 2006).
In two studies, participants in the control group received enhanced
standard care, with NRT alongside a counselling schedule involv-
ing multiple contacts (Lloyd-Richardson 2009; Stanton 2015).
Although in these studies the intervention was still more intense
than the control.
Other study characteristics
The vast majority of included studies were randomised controlled
trials (RCTs). The Ferketich 2013 study was not randomised; par-
ticipants selected their own group (varenicline or NRT) but were
encouraged by study staff to select varenicline, unless medically
contraindicated. The Elzi 2006 study was also not randomised;
all cohort study participants who expressed an interest in quitting
were allocated to the intervention group; the control group in-
cluded the remaining cohort study smokers.
Study inclusion criteria differed on one key point: whether will-
ingness or motivation to quit was explicitly required for inclusion
in the study. Five studies did not refer to motivation or willingness
to quit in their inclusion criteria (Cropsey 2013; Humﬂeet 2013;
Ingersoll 2009; Lloyd-Richardson 2009; Stanton 2015). In Elzi
2006, interest in quitting was required for the intervention group,
but not for the control.
The outcome of cessation was self reported in all studies, which
was biochemically veriﬁed in all except one study (Elzi 2006). Bio-
chemical veriﬁcation was achieved mostly through expired carbon
monoxide. Most studies used a cut-off point of < 7 parts per mil-
lion (ppm) or < 10 ppm, although the lowest cut-off point used
was < 3 ppm (Cropsey 2013). In this study no participants in the
intervention or control groups achieved abstinence veriﬁed by this
low cut-off point, although 22% of the intervention group did
achieve abstinence at the < 10 ppm cut-off point (Cropsey 2013).
In keeping with our protocol, we used the most conservative esti-
mate of abstinence (Pool 2014). Two studies used a combination
of methods for biochemical veriﬁcation; expired carbon monoxide
and urine cotinine, or urine cotinine and nicotine levels.
Only three studies used the outcome measure of sustained absti-
nence. The most commonly used measure was 7-day point preva-
lence smoking abstinence (PPA). One study planned to measure
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both 7-day PPA and sustained abstinence, but the data collected
were insufﬁcient to report sustained abstinence (Shuter 2014).
Excluded studies
We list 22 studies as excluded. Reasons for exclusion can be found
in the Characteristics of excluded studies table.
Risk of bias in included studies
Figure 2 andFigure 3 present the review authors’ judgements about
each risk of bias item as percentages across all included studies.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Two studies reported non-randomised allocation and were there-
fore at high risk of bias for allocation concealment (Elzi 2006;
Ferketich 2013). All studies included in the meta-analysis were
randomised. The method of allocation concealment was generally
not described; only one study explicitly reported method of allo-
cation concealment, but this was not in sufﬁcient detail to permit
judgement of bias.
Blinding
Blinding of participants or personnel was not described in 12 out
of 14 studies, and therefore the risk of these biases was unclear.
In Ferketich 2013, participants chose their group; we therefore
judged this study to be at high risk of performance bias. InManuel
2013, a single provider delivered the counselling to both the in-
tervention and control groups, therefore we judged that it was not
feasible to blind the provider. Due to the nature of the behavioural
interventions, it would have been difﬁcult to blind providers to
participant allocation in most studies.
Blinding of outcome assessment was only reported in detail in two
studies (Lloyd-Richardson 2009; Manuel 2013). In both stud-
ies, researchers blinded to the allocation status of the participant
completed the outcome assessment and we therefore judged these
studies to be at low risk of detection bias. In all other studies, risk
of detection bias was unclear.
Incomplete outcome data
We judged one study to be at high risk of attrition bias (Manuel
2013). In this study, one participant was lost to follow-up and
no data were imputed for them (i.e. not considered missing =
smoking). In addition, of the three participants who reported ab-
stinence, biochemical testing for conﬁrmation of abstinence was
only performed on two specimens of urine, the reason for which
was not explained. We considered the remaining studies to have
low or unclear risk of attrition bias.
Selective reporting
No study authors posted full study results on the clinical trial
registries. We judged ﬁve studies to be at high risk of reporting
bias. The outcome measures were not reported as described in the
protocol in three studies (Humﬂeet 2013; Moadel 2012; Shuter
2014). In each study, the authors stated in the protocol that sus-
tained abstinence and PPA outcomes would be assessed, however
only reported PPA outcomes without explanation. Sustained ab-
stinence data were obtained via communication with the authors
forHumﬂeet 2013, however PPA outcomeswere used in themeta-
analysis since the authors deﬁnition of sustained abstinence (deﬁn-
ing relapse as seven consecutive days of smoking) means that PPA
is the strictest deﬁnition of abstinence.
In Ingersoll 2009, the design of the trial included two groups:
intervention versus control.However, the study authors stated that
there was no difference between the two groups and published only
aggregated data, including baseline characteristics and outcome.
We obtained per group data from the study author for inclusion
in the analysis.
In Cropsey 2013, the authors report measuring expired carbon
monoxide and urine cotinine, but did not report these results.
Other potential sources of bias
We did not judge any studies to be at risk of ’other’ bias.
Effects of interventions
See: Summary of findings for the main comparison Tobacco
use cessation in people living with HIV and AIDS
Long-term cessation
For long-term abstinence, a pooled estimate combining the six
included studies showed no evidence of effect for the intervention
(risk ratio (RR) 1.00, 95% conﬁdence interval (CI) 0.72 to 1.39;
moderate quality evidence) with no evidence of heterogeneity (I2
= 0%) (Analysis 1.1; Figure 4; Summary of ﬁndings for the main
comparison). Abstinence in the control group at long-term follow-
up was 8% (n = 69/842) and in the intervention group was also
8% (n = 61/760).
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Figure 4. Forest plot of comparison: 1 Tobacco cessation intervention versus control, outcome: 1.1
Proportion of participants abstinent.
Wedid not create a funnel plot for the long-term outcome because
fewer than 10 studies were included.
Short-term cessation
For short-term abstinence, a pooled estimate of the 11 included
studies showed beneﬁt of intervention (RR 1.51, 95% CI 1.15
to 2.00; very low quality evidence) with moderate heterogeneity
(I2 = 42%) (Analysis 2.1; Figure 5; Summary of ﬁndings for the
main comparison). Abstinence in the control group at short-term
follow-up was 8% (n = 67/848) and in the intervention group was
13% (n = 118/937).
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Figure 5.
For the short-term outcome, a funnel plot showed some evidence
of asymmetry, suggesting the possibility of publication bias (Figure
6).
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Figure 6. Funnel plot of comparison: 2 Tobacco cessation intervention versus control, outcome: 2.1 Short-
term abstinence (4 weeks to < 6 months).
We undertook a sensitivity analysis, removing smaller studies, and
this did not signiﬁcantly change the pooled estimate. We under-
took a sensitivity analysis according towhetherNRTor varenicline
was given; it did not signiﬁcantly change the pooled estimates for
long-term or short-term abstinence (Analysis 3.1; Analysis 3.2).
Only one study included in the meta-analysis used varenicline
(Shelley 2015).We undertook a further sensitivity analysis accord-
ing to the degree of intervention provided to the control: no input,
standard care, or enhanced standard care. Two studies provided
enhanced standard care (Lloyd-Richardson 2009; Stanton 2015);
as may be expected the quit rate observed amongst controls was
higher in these studies compared to controls receiving standard
care or no input. For short-term outcomes, in the sensitivity anal-
ysis excluding these studies, the pooled estimate for the effect of
the intervention increased slightly (Analysis 4.2). For long-term
outcomes, the pooled estimate did not markedly change (Analysis
4.1).
Subgroup analyses
Effect of provider
We categorised the provider of the behavioural intervention as
follows: healthcare professional, researcher, or co-facilitation by a
peer and professional (Analysis 5.1). We failed to detect evidence
of a difference in the effect according to provider in the analysis
for long-term abstinence. For short-term outcomes, the pooled
estimate for interventions that were co-facilitated by a peer and
professional (RR 2.52, 95% CI 1.14 to 5.56) were slightly larger
than for other providers (healthcare professional alone: RR 1.41,
95% CI 0.98 to 2.03; and researcher: RR 2.56, 95% CI 0.72 to
9.04). However, the CIs overlapped.
Effect of mode of contact
We failed to detect evidence of an effect of subgroup categorisa-
tion by mode of contact for long-term abstinence (Analysis 6.1).
For short-term outcomes, the pooled estimate was highest for in-
terventions delivered via telephone (RR 3.69, 95% CI 1.80 to
7.53; Analysis 6.2). This was predominantly driven by the effect
of one, large study (Vidrine 2012). There were few studies in
some subgroups, which limits the conclusions possible from this
subgroup analysis; only one intervention was delivered via text
message (Shelley 2015), and two were delivered via computers
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(Humﬂeet 2013; Shuter 2014).
Participant selection
We failed to detect evidence of an effect of participant selection
for long-term abstinence (Analysis 7.1). For short-term outcomes
there is evidence of a difference in effect according to whether
willingness or motivation to quit was required for participant in-
clusion (Analysis 7.2). The subgroup of participants who were
selected for their willingness or motivation to quit had a higher
pooled estimate of effect (RR 2.74, 95%CI 1.73 to 4.34, I² = 0%)
compared to the subgroup for whom this was not required (RR
0.94, 95% CI 0.65 to 1.35, I² = 0%).
Tailoring
All studies which reported long-term outcomes provided a tailored
intervention, and one of these studies even tailored the control
(Shelley 2015); therefore it was not possible to compare tailored
to generic interventions for long-term abstinence (Analysis 8.1).
For short-term outcomes, there was no strong evidence of a dif-
ference in effect for interventions tailored for PLWHA compared
to generic interventions (Analysis 8.2). The comparison was lim-
ited due to the small number of studies providing a generic inter-
vention. Only two studies provided a generic intervention, and in
one of these, no participants in the intervention or control arm
achieved abstinence at the level of biochemical veriﬁcation set by
the authors (Cropsey 2013).
Intensity
The investigation of intensity of behavioural intervention, via
number of sessions and total duration of contact for long-term
abstinence, was a post hoc objective; we failed to detect evidence
of a difference in effect according to either number of sessions or
duration of total intervention (Analysis 9.1; Analysis 10.1). There
were few studies in each subgroup. Intensity subgroup analyses
were not completed for short-term outcomes because the inter-
vention may not have been completed at the time of short-term
outcome assessment.
Adverse events
It was not possible to perform a quantitative synthesis of adverse
events, since only one study reported them in detail (Ferketich
2013).
HIV outcomes
It was not possible to perform the planned quantitative synthesis
of HIV outcomes - CD4 count, viral load, and incidence of op-
portunistic infections - since only one study reported them (Elzi
2006).
D I S C U S S I O N
Summary of main results
This systematic review provides evidence from 14 studies. More
than 1600 participants from 12 studies contributed to the meta-
analysis for the primary outcome of long-term abstinence.
In this review we found that more intense combined interventions
of pharmacotherapy and behavioural support were effective in in-
creasing the chance of achieving abstinence in the short-term (four
weeks to less than six months) compared to a control group that
typically included a single brief intervention and pharmacother-
apy. The pooled estimate for short-term outcomes (risk ratio (RR)
1.51, 95% conﬁdence interval (CI) 1.15 to 2.00) indicates that a
combined intervention might typically increase cessation success
by 15% to 100%. However, this effect was not observed for long-
term abstinence (greater than six months).
There are differences between studies - in particular whether par-
ticipants were selected for their willingness or motivation to quit.
Those studies including only motivated or willing participants
showed a larger pooled estimate of the effect of the intervention
for short-term outcomes, although this was not observed at long-
term follow-up.
As noted, we were unable to assess one of the original objec-
tives - whether interventions combining pharmacotherapy and be-
havioural support were more effective than either type of support
alone. This was because all included studies assessed a combined
intervention compared to control. We added a post hoc objective
assessing the effect of intensity of behavioural intervention. This
analysis did not ﬁnd any evidence of a difference in the effect of
intensity. Although this subgroup analysis was limited by the small
number of studies and does not deﬁnitively indicate that increas-
ing the intensity would not result in an increased effect. In the
general population, Stead 2016 also found no evidence that more
intensive support increased the effect of treatment. Our analysis
according to intensity only included personal contact time via tele-
phone or in person. This may have underestimated the impact of
interventions delivered via computers or text messages.
Subgroup analysis was undertaken according to whether the inter-
vention was tailored for people living with HIV/AIDS (PLWHA).
We failed to detect evidence of a difference in effect for tailored
interventions for short-term abstinence, although this analysis was
limited by a small number of studies providing a generic interven-
tion. Subgroup analysis by tailoring was not possible for long-term
outcomes because all studies provided a tailored intervention.
Overall completeness and applicability of
evidence
All studies included in the meta-analysis were undertaken in the
US, although they do encompass a range of demographic proﬁles.
There are health system and socioeconomic differences between
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the US and Europe, as well as between the US and sub-Saharan
Africa, where the majority of PLWHA live (UNAIDS 2015). This
limits the generalisability of these results. Among ongoing studies,
most are based in North America, although NCT01484340 is
based in South Africa.
There remains a lack of studies which have large sample sizes and
that assess long-term abstinence (greater than six months).
Quality of the evidence
We evaluated the overall quality of the evidence according to
GRADE criteria. For the primary outcome of long-term cessation,
we judged the quality of evidence to be moderate. The quality of
the evidence was downgraded due to risk of bias; one study was
judged to be at high risk of reporting bias, and allocation conceal-
ment and blinding were poorly described.
For the secondary outcome of short-term cessation, we judgedthe
quality of evidence to be very low due to inconsistency, in addition
to reporting and detection biases.
We judged ﬁve studies to be at high risk of reporting biases where
outcomes described in the protocol were not accounted for in the
published reports. Although, in most cases communication with
the study authors resulted in additional data being made available,
or the study authors provided an explanation as to why they were
unable to report the proposed outcomes. Allocation concealment
and blinding were poorly described and therefore we assessed most
studies to have ’unclear’ judgements in these areas. There was also
a high proportion of small studies, which reﬂects that this is a
relatively new area of research. The rationale for upgrading or
downgrading the quality of the body of evidence is presented in
Summary of ﬁndings for the main comparison.
Potential biases in the review process
There is evidence of possible publication bias in the funnel plot
for short-term outcomes, despite substantial effort being made to
locate studies within the grey literature. Although we did identify
some attrition bias and reporting bias, the impact of these were
reduced through correspondence with authors to clarify points or
request additional data. Additional data were kindly provided in
most of these cases.
We added one objective post hoc - assessing the impact of inten-
sity of the behavioural intervention on abstinence, and therefore
potentially introducing some bias. However, we felt it was logical
and consistent with the ethos of the original objective - to assess
whether combined interventions are more effective than pharma-
cotherapy and behavioural support alone.
As is standard for Cochrane Reviews, all reports were reviewed and
all data were extracted in duplicate in order to reduce bias.
Agreements and disagreements with other
studies or reviews
We believe that this is the ﬁrst systematic review of tobacco ces-
sation interventions for PLWHA to include meta-analysis. A pre-
vious systematic review provided a narrative overview and in-
cluded some studies excluded by our stricter inclusion criteria
(Moscou-Jackson 2014).
In the general population, interventions that combine behavioural
and pharmacotherapy components have been shown to be effec-
tive for long-term abstinence when compared to a brief interven-
tion without pharmacotherapy (Stead 2016), the reason for this
effect not being observed in PLWHA is not clear. In the general
population, tailoring cessation interventions has been shown to
increase their effect (Hartmann-Boyce 2014). This was not shown
in this review, but our comparison was limited by a small number
of studies with a non-tailored generic intervention. It is important
to consider that the evidence presented here is limited and has been
judged to be of very low to moderate quality. There is much more
and higher quality evidence assessing smoking cessation interven-
tions and ﬁnding them effective in the general public. Therefore,
it would be too premature to say that interventions aimed at the
general population will not beneﬁt PLWHA.
However, the following could explain a less pronounced effect.
People living with mental illnesses have some similarities to
PLWHA; they usemore tobacco than the general population, often
consume tobacco alongside drugs or alcohol, and may use tobacco
to cope with their illness or treatment side effects (Tsoi 2013). In
Tsoi and colleagues’ review of smoking cessation interventions for
people with schizophrenia they found that at short-term follow-
up there was evidence in favour of a combined intervention (coun-
selling and nicotine replacement therapy (NRT)) (Tsoi 2013), but
long-term follow-up failed to detect evidence of a difference be-
tween the intervention and control. Their results echo the results
of this meta-analysis and could reﬂect a higher potential for relapse
in people with complex chronic diseases and multiple challenges.
However, the comparison is limited, as the two populations have
distinct differences, both medically and psychosocially.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of this review must be considered in the context of
the small number of studies included and the low to moderate
quality of the evidence, and it therefore should not be ruled out
that smoking cessation interventions that have been found to work
in the general population will not have an effect in PLWHA.
More intense combined interventions of pharmacotherapy and be-
havioural support were shown to be effective in assisting PLWHA
to achieve short-term abstinence, when compared to controls in
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this review; however this effect was not observed at long-term
follow-up. This could be a function of study biases. Therefore,
evidence suggests that clinicians should offer a combined inter-
vention to PLWHA who use tobacco, at least comprising a brief
behavioural intervention with pharmacotherapy, since even non-
sustained periods of abstinence have proven health beneﬁts. The
effects of tailoring, number of contacts and total duration of con-
tact of behavioural support remain unclear.
Implications for research
Further randomised controlled trials (RCTs) of tobacco cessation
interventions in PLWHA are needed; they should include a large
sample size and ensure that follow-up continues for at least six
months, and preferably 12 months.
In this review, there was evidence of effectiveness of the interven-
tion at short-term follow-up; however, we rated the quality of this
evidenceas ’very low’ according to GRADE, and we did not ob-
serve any effect at long-term follow-up. Further research is needed
to address the potential biases in the existing literature, including
investigating relapse prevention in PLWHA who achieve short-
term abstinence. This would maximise the probability of short-
term success being translated into long-term abstinence.
Trials assessing the impact of tailoring and intensity of interven-
tions are also needed. Data on sexual orientation should be rou-
tinely collected and reported in studies of PLWHA. Tobacco con-
sumption may effect treatment response, as such, future studies
measuring HIV outcomes - CD4 count, viral load, and incidence
of opportunistic infections - would be highly informative. The fact
that almost all studies are based in the US limits generalisability
due to population and health system differences. Further studies
should be based in a range of contexts, particularly in low- and
middle-income countries with a high burden of HIV and tobacco
consumption.
Future studies should ensure that reporting is in line with CON-
SORT criteria (Schulz 2010), particularly with regard to blinding
and allocation concealment.None of the included studies reported
their study in line with these criteria and as such, we judged many
to be of ’unclear’ risk of bias.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cropsey 2013
Methods Country: US
Design: paralell, pilot RCT
Number of centres: 1
Selection: invited to participate during appointments
Deﬁnition of tobacco user/smoker: self report ≥ 5 cpd
Participants Number: 40 participants
Average age: 44.5 years
Gender: 48% male
Sexuality: not reported
Race/ethnicity: 58% Black
cpd: 19 cpd in intervention group, 15.5 cpd in control group
Mean FTND score: 6.0 in intervention group, 6.5 in control group
Interventions 1. Intervention: one informational session for 20minutes, delivered by a research assistant
face-to-face. NRT, 14 mg patches and 2 mg lozenges for four weeks
2. Control: no intervention by research team
Provider: research assistant (Bachelors level)
Tailoring: neither intervention nor control were tailored for PLWHA
Outcomes Abstinence: self reported PPA at 2, 4, and 8 weeks post-enrolment
Validation: exhaled CO < or equal to 2 ppm
Notes Cessation was not a primary outcome of the study. The cessation outcomes were not
published but were obtained following correspondence with the author
Funding: Centers for AIDS Research grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Particpants were randomised using a ran-
dom numbers table
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Participantswere asked questions and given
questionnaires, the process is insufﬁciently
described to permit judgement
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Cropsey 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5 participants were excluded. The distribu-
tion of missing participants was balanced
between groups (3:2)
The reasons for missing data are insufﬁ-
ciently described to permit judgement
Selective reporting (reporting bias) High risk Biochemical veriﬁcation of abstinence (by
eCO and urine cotinine) was planned but
not reported These data were obtained via
communication with the author
Elzi 2006
Methods Country: Switzerland
Design: parallel, pilot controlled trial within Swiss HIV Cohort Study
Number of centres: 1
Selection: participants who expressed an interest in quitting smoking were invited to
participate; control group participants were smokers not interested in quitting
Deﬁnition of tobacco user/smoker: self report ≥ 1 cpd for > 12 months
Participants Number: 417 (33 died, therefore excluded from ﬁnal analysis)
Average age: 43 years in intervention group, 40 years in control group
Gender: 69% male
Sexuality: not reported
Race/ethnicity: 87% White
cpd: 28 cpd in intervention group, 21 cpd in control group
FTND score: > 7 for 74% in intervention group, not reported in control group
Interventions 1. Intervention: 15 individual face-to-face counselling sessions based on CBT. Sessions
were 30 minutes duration and took place weekly during the ﬁrst month, and monthly
thereafter for 12 months. NRT patches, tablets, chewing gum, and sprays were offered
to all participants; dose and duration not stated
2. Control: no intervention
Provider: nurse trained in smoking cessation counselling
Tailoring: the intervention was not described as tailored to PLWHA
Outcomes Abstinence: self reported sustained abstinence at 12 months or greater
Validation: no biochemical validation
Notes This study was not included in the meta-analysis due to study design and heterogeneity
Funding: the Swiss HIV Cohort Study is supported by the Swiss National Science Foun-
dation
Deaths: in the intervention group, 1/34 (3%) participants died of lung cancer. In the
control group, 32/383 (8%) died during the study period. Of these deaths, 11 wereHIV-
related, including one related to lung cancer and one related to cardiovascular disease
Risk of bias
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Elzi 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not randomised “participation in the pro-
gramme [intervention group] was offered
to those individuals who expressed an in-
terest to quit smoking”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described in sufﬁcient detail to permit
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Smoking status extracted from routine
clinic data, but clinician blinding not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Low risk The distribution of missing participants
was balanced between groups. Explana-
tions were provided
Selective reporting (reporting bias) Low risk Primary outcome was reported in full
Ferketich 2013
Methods Country: US
Design: parallel, non-randomised controlled study, safety study
Number of centres: 1
Selection: participants were recruited from within the Lung HIV study, interest in quit-
ting was an inclusion criterion
Deﬁnition of tobacco user/smoker: self report ≥5 cpd
Participants Number: 228
Average age: 43 years in intervention group, 43 years in control group
Gender: 86% male in intervention group, 85% male in control group
Sexuality: not reported
Race/ethnicity: 61% White in intervention group, 50% White in control group
cpd: 19.7 cpd in intervention group, 20 cpd in control group
Mean FTND score: 4.9 in intervention group, 5.4 in control group
Interventions 1. Intervention: varenicline, titrated up to 1 mg twice daily. 12 weekly individual coun-
selling sessions, ﬁrst session face-to-face, all following sessions via telephone
2. Control: NRT 21 mg patch per day plus 4 mg gum as required to a maximum of 24
pieces per day. Counselling as per intervention group
Provider: advanced practice nurse “experienced in delivering tobacco dependence treat-
ment”
Tailoring: neither intervention nor control were tailored for PLWHA
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Ferketich 2013 (Continued)
Outcomes Abstinence: self reported 7-day PPA at 12 weeks post-initiation of treatment, TQD was
set at approximately week 3, therefore abstinence assessment is approximately 9 weeks
post-TQD
Validation: eCO < 10 ppm for participants not using NRT, saliva cotinine < 15 ng/ml
for participants using NRT
Notes Funding: National Institutes of Health grant
This study was not included in the meta-analysis as it was designed to compare phar-
macotherapy and was not in keeping with the comparison of intervention versus less
intense control
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not randomised, “participants were en-
couraged to select varenicline” unless it was
contraindicated in which case they were as-
signed to the control NRT group
Allocation concealment (selection bias) High risk Allocation was according to participant se-
lection and not concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessed by face-to-face inter-
view, insufﬁciently described to permit
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Proportion of participants missing was
approximately balanced between groups.
Missing data imputed as missing = smok-
ing
Selective reporting (reporting bias) Low risk Primary outcomes reported in full
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Humfleet 2013
Methods Country: US
Design: parallel, three-group RCT
Number of centres: 3
Selection: participant self referral or clinician referral. Postcards and ﬂyers at clinics,
letters sent to patients
Deﬁnition of tobacco user/smoker: self report smoking most days in a month
Participants Number: 209
Average age: 45 years
Gender: 82% male
Sexuality: 62% Gay/Lesbian, 24.3% straight, 7.4% bisexual
Race/ethnicity: 53% White
Average cpd: 19.8
Mean FTND score: 4.9
Interventions 1. Computer-based intervention: one face-to-face orientation meeting of 45-60 minutes.
Six counselling sessions based on CBT, delivered via a website, in addition to message
board and ‘ask the experts’ options on the website. Mean duration on website 30-45
minutes. 10 weeks of NRT, patch or gum, available to participants who smoked ≥ 5
cpd; dose not stated
2. Individual counselling: six individual, face-to-face sessions based on CBT over 12
weeks. Session duration 40-60minutes. NRT as perComputer-based intervention group
3. Control: one-off, brief, face-to-face meeting with research staff and written reference
guide provided. NRT as per the intervention groups
Provider of individual counselling: “clinicians with a master’s or doctoral degree in social
work or psychology and had previous experience in smoking cessation treatment”
Tailoring: individual counselling was tailored via focus on impact of smoking on HIV,
stress, depression, low social support and HIV-related health issues. CBI was described
as modelled on individual counselling and therefore assumed to be tailored. Control was
not described as tailored
Outcomes Abstinence: 7-day PPA and sustained abstinence at 12, 24, 26, and 52 weeks following
intervention. In individual counselling group TQD was in week 2. TQD is not clearly
described for CBI or control groups
Validation: PPA outcomes were veriﬁed by eCO ≤ 10 ppm, the sustained abstinence
outcomes were not biochemically veriﬁed
Notes PPA and sustained abstinence outcomes were measured but sustained outcomes were
not described in detail in the published report. The sustained outcome data for meta-
analysis were obtained via email communication with the authors
Funding: NIDA grants and California TRDRP grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were “randomized via com-
puter algorithm to one of three conditions
in 1:1:1 fashion into a parallel group de-
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Humfleet 2013 (Continued)
sign”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described in sufﬁcient detail to permit
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Proportion of missing participants was
evenly balanced between groups
Selective reporting (reporting bias) High risk The study was registered on clinicaltri-
als.gov NCT00297453. The primary out-
come measure of smoking cessation was
measured byPPA and sustained abstinence,
but sustained abstinence results were not
reported in full
Ingersoll 2009
Methods Country: US
Design: parallel RCT
Number of centres: 1
Selection: ﬂyers and self referral or direct contact with researcher
Deﬁnition of tobacco user/smoker: self report smoking daily
Participants Number: 40
Average age: 42 years
Gender: 55% male
Sexuality: not reported
Race/ethnicity: 95% Black
Average cpd: 17.3
Mean FTND score: 5.0
Interventions 1. Intervention: one individual face-to-face counselling session, based on MI. NRT
provided according to volume of tobacco consumed. If participants smoked > 10 cpd;
21 mg NRT patch for 1 month, 14 mg patch for 2 weeks and 7 mg patch for two weeks.
If participants smoked < 10 cpd; 14 mg patch for 2 weeks and 7 mg patch for two weeks
2. Control: written materials to facilitate self assessment and tips for cessation. One-off
face-to-face session where the materials were reviewed, but no counselling was provided.
NRT as per intervention group
Provider: post-doctoral fellow or counsellor
Tailoring: the intervention was tailored through a focus on risk of smoking in the context
of HIV. Control was not tailored for PLWHA
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Ingersoll 2009 (Continued)
Outcomes Abstinence: self report PPA at 1 and 3 month follow-up
Validation: eCO < 3 ppm
Notes Additional data were obtained following correspondence with the author. In the pub-
lished report the data from the two groups were added and presented as one data set
Funding: NIH K01MH10688, NIH K23DA15774, and VCU’s Institute for Drug and
Alcohol Studies
Conﬂicts of interest: Glaxo Smith Kline provided nicotine patches for the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...participants were randomly assigned to
one of two treatment conditions” but se-
quence generation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome was assessed by self report and
eCO, process not described in sufﬁcient de-
tail to permit judgement of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants (5) is reported but
distribution is not described and explana-
tions not given
Selective reporting (reporting bias) High risk The design was a two-group trial but the
results were aggregated and only reported
as a whole
Lloyd-Richardson 2009
Methods Country: US
Design: parallel RCT
Number of centres: 8 (6 outpatient HIV clinics and 2 primary care centres)
Selection: participants were recruited at their clinic
Deﬁnition of tobacco user/smoker: self report ≥5 cpd
Participants Number: 444
Average age: 42 years
Gender: 63% male
Sexuality: not reported
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Race/ethnicity: 52% White
cpd: 18.2 cpd
Mean FTND score: 5.9
Interventions 1. Intervention: 1 brief advice session, plus 4 face-to-face individual counselling sessions
based on MI and a quit day phone call. Duration of each counselling session was 30
minutes. Participants willing to set a TQD were provided with NRT patches, 8 weeks
duration; dose not described
2. Control: 2 brief advice sessions, delivered face-to-face and self help written materials.
In addition, participants willing to set a TQD received biweekly brief sessions (5minutes
duration) to reinforce quit effort, check patch side effects and distribute NRT patches.
NRT provided as per intervention group
Provider: health educator trained in smoking cessation
Tailoring: Intervention was tailored via an emphasis on the impact on infections and
immunity. Control was not tailored for PLWHA
Outcomes Abstinence: 7-day PPA at 2, 4, and 6 months post-enrolment
Validation: eCO < 10 ppm
Notes The published report included percentage abstinence rate only; the number of partic-
ipants abstinent were calculated as we were unable to be obtain these via email corre-
spondence with the authors
Funding: NIDA grant, the National Heart, Lung, and Blood Institute grant, National
Cancer Institute grant, an NIH-funded Transdisciplinary Tobacco Use Research Center
Award grant, NIH-funded Lifespan/Tufts/Brown Center for AIDS Research Award, and
by the Robert Wood Johnson Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were then randomized (using
block randomization to ensure stratiﬁca-
tion by gender and level of motivation to
quit smoking)”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described in sufﬁcient detail to permit
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Follow-up assessments were administered
by research staff blinded to participant in-
tervention assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Proportion of missing participants is bal-
anced between groups. A missing = smok-
ing assumption was used
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Selective reporting (reporting bias) Low risk All of the primary outcomes were reported
in full. A study protocol was published
on clinicaltrials.gov (NCT00551720), the
published method and outcomes correlate
with the protocol methods and outcomes
Manuel 2013
Methods Country: US
Design: parallel RCT
Number of centres: 1
Selection: participants were recruited at their clinic through ﬂyers and clinician referrals.
Participant interest in quitting was an inclusion criterion
Deﬁnition of tobacco user/smoker: self reports of smoking daily for at least ﬁve of the
last seven days
Participants Number: 30
Average age: 49 years
Gender: 100% female (being female was an inclusion criterion)
Sexuality: 67% heterosexual
Race/ethnicity: 47% Black
cpd: 15.5 in intervention, 16.7 in control
Mean FTND score: 4.1 in intervention, 5.0 for control
Interventions 1. Intervention: 1 face-to-face counselling session, based on MI. Average duration 27
minutes. Participants were referred to NRT programmes, but dose, duration and fre-
quency of NRT not described
2. Control: 1 face-to-face session and written materials. Written materials were reviewed
and strategies discussed. Duration not described. NRT as per the intervention
Therapist: “highly experienced MI clinician”
Tailoring: neither intervention nor control were tailored for PLWHA
Outcomes Abstinence: 7-day PPA at 1 month follow-up
Validation: urine nicotine and cotinine, scale not described
Notes Funding: NIDA grant, the NIDA San Francisco Treatment Research Center grant, and
University of California’s Center for AIDS Prevention grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A “permuted block randomization” tech-
nique was used
Allocation concealment (selection bias) Unclear risk Sealed envelopes were used but safeguards
not described in sufﬁcient detail to per-
mit judgement: “the interviewer opened a
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sealed envelope indicatingwhich condition
the participant had been randomized to re-
ceive”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not clearly described, but a single thera-
pist delivered both control and interven-
tion treatments therefore blinding is unfea-
sible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “RA was blind to the participants’ treat-
ment condition”
Incomplete outcome data (attrition bias)
All outcomes
High risk 1 participant lost to follow-up and no data
imputed. Of the 3 people who reported
abstinence, only two urine samples were
taken, no explanation provided
Selective reporting (reporting bias) Low risk Primary outcomes are all reported
Moadel 2012
Methods Country: US
Design: parallel RCT
Number of centres: 1
Selection: Participants were referred via clinicians or recruited in the waiting room,
motivation to quit (> 6 on the readiness ladder) was required for inclusion
Deﬁnition of tobacco user/smoker: self reported use of any product containing nicotine
(cigarettes, pipes or cigars) in the past 5 days
Participants Number: 145
Average age: 49 years
Gender: 49% male
Sexuality: not directly reported, HIV risk group was ’same sex contact’ for 14.5% and
’heterosexual contact’ for 57.9%
Race/ethnicity: 86% Black
cpd: 12.0 cpd
Mean FTND score: 5.0
Interventions 1. Intervention: eight group counselling sessions of six to eight participants. Sessionswere
based on social cognitive theory principles and occurred weekly (90 minutes duration).
Participants were offered three months of NRT; dose and mode of delivery not described
2. Control: one-off, face-to-face brief advice (< 5 minutes) to quit and written materials
were provided. NRT as per intervention
Provider: co-facilitated by one professional (psychology graduate student and ex-smoker)
and one peer (PLWHA ex-smoker). Both “completed certiﬁed courses in tobacco treat-
ment”
Tailoring: intervention was tailored through use of a HIV-positive peer and highlighting
the speciﬁc risks of smoking for PLWHA. The control was not tailored for PLWHA
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Outcomes Abstinence: 7-day PPA at days 0, 42, and 132; assessment at 3 months from TQD
Validation: eCO < 10 ppm
Notes NRTwas the only cessationmedication offered to trial participants, although the authors
report that some participants also obtained bupropion or varenicline outside of the study
protocol
Funding: NIH/NIDA grant, Clinical Core of the Center for AIDSResearch at the Albert
Einstein College of Medicine and Monteﬁore Medical Center funded by a NIH grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects who provided consent were ran-
domized in a 1:1 schedule to the two study
conditions”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described in sufﬁcient detail to permit
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk The distribution of missing participants
was balanced between groups (4 from inter-
vention and 2 from control). Missing data
imputed as missing = smoking
Selective reporting (reporting bias) High risk The study was registered on clinicaltrials.
govNCT01106638. A secondary outcome
measure of ’continuous abstinence’ was de-
scribed in the protocol but not reported
Shelley 2015
Methods Country: US
Design: paralell RCT
Number of centres: 3
Selection: participants were recruited from HIV care centres, willingness to quit within
the next two weeks was required for inclusion
Deﬁnition of tobacco user/smoker: at least 5 cpd
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Participants Number: 158
Participant characteristics are for 127 participants (outcome data are for all 158 partici-
pants)
Average age: 50 years
Gender: 84% male
Sexuality: not reported
Race/Ethnicity: 48% Black
cpd: 15 cpd
Mean FTND score: not reported
Interventions Intervention 1. Text messages : adherence-focused twice daily text messages. 12 weeks
of varenicline. Based on Information Motivation Behaviour model
Intervention 2. Adherence Behavioural Therapy : adherence-focused twice daily text
messages, plus 7 sessions of telephone counselling. Planned duration of call: 20-30
minutes. Based on Information Motivation Behaviour model. 12 weeks of varenicline
3. Control/standard care: 12 weeks of varenicline, dose and frequency not reported.
Information sheet and State Quitline number provided. Participants in intervention
groups also received control
Provider: trained counsellors (Masters level)
Tailoring:text messages were tailored through conveying information considered partic-
ularly relevant to PLWH, but did not use the terms HIV/AIDS to ensure conﬁdentiality.
Adherence Behavioural Therapy intervention discussed the effects of smoking on HIV
and focused on speciﬁc barriers for PLWH. The self help information sheet given as
standard care was tailored to PLWH
Outcomes Abstinence: 7-day PPA at weeks 1, 4, 8, 12, and 24 from start of treatment
Validation: eCO < 8 ppm
Notes The study was registered on clinicaltrials.gov NCT01898195
In published reports, 1 month per protocol outcomes were reported. 24 week intention-
to-treat outcomes were obtained following correspondence with the author. Funding:
NIDA and Centre for Drug and HIV Research
Conﬂicts of interest: Pﬁzer provided study medication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...participants were randomly assigned to
one of two treatment conditions” but se-
quence generation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcome assessed by self report and eCO.
Proportion of missing participants not de-
scribed per group. Overall, insufﬁciently
described to permit judgement
Selective reporting (reporting bias) Unclear risk Outcome assessed by self report and eCO.
Proportion of missing participants not de-
scribed per group. Overall, insufﬁciently
described to permit judgement
Shuter 2014
Methods Country: US
Design: parallel RCT
Number of centres: one
Selection: recruited at HIV clinic, interest in quitting was required for inclusion
Deﬁnition of tobacco user/smoker: self reported use of cigarettes, pipes or cigars in the
past ﬁve days
Participants Number: 138 (2 died, therefore excluded from ﬁnal analysis)
Average age: 46 years
Gender: 60% male
Sexuality: not directly reported, HIV risk group was ’same sex contact’ for 37% and
’heterosexual contact’ for 44.2%
Race/ethnicity: 60% Black
cpd: 10.2 cpd in intervention, 11.5 cpd for control
Mean FTND score: 4.8 in intervention, 4.9 in control
Interventions 1. Intervention: eight interactive web-based sessions, independently completed once a
week, based on social cognitive theory. Mean time spent logged into the website; 59.8
minutes. NRT patches for three months were offered, dose and frequency not described
2. Control: brief advice (< 5 minutes duration) to quit and written materials. NRT as
per intervention
Provider: intervention was web-based
Tailoring: the intervention was tailored to PLWHA through comparison of changes in
HIV risk behaviour and smoking behaviour. Control was not tailored
Outcomes Abstinence: 7-day PPA at 6 weeks and 3 months post-TQD
Validation: eCO < 10 ppm
Notes Draft report made available by authors prior to publication date
Deaths: 2 participants died during the study period, 1 in control and 1 in intervention.
Their deaths were not considered related to the study
They were excluded in the reanalysis. Number abstinent were not reported (percentage
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abstinent were reported) in the publication, theywere obtained via email communication
with the author
Funding: NIH/NCI grants, Clinical Core of the Center for AIDS Research at the Albert
Einstein College of Medicine and Monteﬁore Medical Center funded by the NIH grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “... eligible subjects were randomized by
study staff 1:1 into 2 conditions using a
random number table and an even/odd al-
location strategy”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described in sufﬁcient detail to permit
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessment was by self admin-
istered questionnaire and eCO. Not de-
scribed in sufﬁcient detail to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The distribution of missing participants
was balanced between groups (1 in inter-
vention group, 3 in control group). Expla-
nations were provided. Missing data im-
puted as missing = smoking
Selective reporting (reporting bias) High risk The methods in the report do not corre-
late with the protocol. The study was regis-
tered on clinicaltrials.gov NCT01570595.
Primary and secondary outcomes differed
in the published report compared to the
protocol
Stanton 2015
Methods Country: US
Design: parallel RCT
Number of centres: 9
Selection: clinician referral from immunology clinics
Deﬁnition of tobacco user/smoker: self report smoking cigarettes in the past 7 days
Participants Number: 302
Average age: 45 years
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Gender: 64% male
Sexuality: not reported
Race/ethnicity: 100% Latino (being Latino was required for inclusion)
cpd and mean FTND score were not reported
Interventions 1. Intervention: as per control plus two additional face-to-face individual counselling
sessions (average duration of session 1: 62minutes) and two additional tenminute phone
calls, provided by health educator. All sessions culturally tailored to Latino. Option to
bring a ‘support buddy’, culturally sensitive written materials and videos. If willing to
set a TQD received NRT for 8 weeks, dose according to smoking level
2. Control: physician brief advice, plus two face-to-face individual counselling sessions
andone quit day phone call (tenminutes), andwrittenmaterials.NRTas per intervention
Provider: health educator “at least Masters level professionals (or had equivalent years
of clinical research experience) and were trained on the implementation of the manual
driven interventions”
Tailoring: the intervention was tailored being both a PLWHA and a Latino, emphasis on
the speciﬁc health consequences of smoking on HIV. Control not tailored to PLWHA
or Latino
Outcomes Abstinence: 7-day PPA at 6 and 12 months post-intervention
Validation: eCO < 10 ppm
Notes Additional data and study design details were obtained via email communication with
the authors ahead of full report publication
Funding: NIDA grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participantswere randomised “using anurn
randomisation procedure” and stratiﬁed by
gender
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described in sufﬁcient detail to permit
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk The distribution of missing participants
was balanced between groups (54 from
control group, 68 from intervention group)
. Missing data imputed as missing = smok-
ing
43Interventions for tobacco use cessation in people living with HIV and AIDS (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stanton 2015 (Continued)
Selective reporting (reporting bias) Low risk The study was registered on clinicaltrials.
gov NCT00503230 and all primary out-
comes were reported in full
Vidrine 2006
Methods Country: US
Design: parallel RCT
Number of centres: 1
Selection: all patients screened at clinic appointments and invited if eligible. Willingess
to set a quit date within 7 days was required for inclusion
Deﬁnition of tobacco user/smoker: self report ≥5 cpd and eCO > 7 ppm
Participants Number: 94 (1 participant died, therefore excluded in reanalysis)
Average age: 43 years in intervention group, 43 years in control
Gender: 78% male
Sexuality: not directly reported, HIV risk group was ’same sex contact’ for 37.9% and
’heterosexual contact’ for 35.8%
Race/ethnicity: 72% Black
cpd: 20.6 cpd in intervention group, 19.5 in control
Mean FTND score: 5.5 in intervention group, 5.7 in control
Interventions 1. Intervention: eight counselling sessions over two months, plus access to a hotline.
Delivered via cell phone and based on CBT. NRT patches provided for ten weeks. All
intervention participants also received control
2. Control: one session of brief advice, face-to-face. NRT patches provided for ten weeks.
Written materials; personal plan, self-help guide and tip sheet
Provider: ”research assistant (with a master’s level qualiﬁcation) trained in smoking ces-
sation counselling“
Tailoring: the intervention was tailored to PLWHA through emphasising the impact of
smoking on the immune system and HIV-related diseases. Control tip sheet was tailored
to PLWHA
Outcomes Abstinence: self reported PPA and sustained abstinence
Validation: eCO < 7 ppm
Notes Funding: National Cancer Institute grant and the Margaret and James A. Elkins, Jr
Faculty Achievement Award in Cancer Prevention
1 death reported in the control group. Reanalysis of data undertaken excluding this
participant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised via ”adap-
tive randomization designed to minimize
imbalances in the distribution of prog-
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nostic factors (i.e. depression, number of
cigarettes smoked per day, and level of nico-
tine dependence”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessed by face-to-face interview
and eCO, the process was insufﬁciently de-
scribed to permit judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk The distribution of missing participants
was balanced between groups (10 from in-
tervention group, 8 from control group).
Explanations were provided. Missing data
imputed as missing = smoking
Selective reporting (reporting bias) Low risk Protocol not published, but all primary
outcomes were reported in full
Vidrine 2012
Methods Country: US
Design: parallel RCT
Number of centres: 1
Selection: patients screened at clinic appointments and invited if eligible, willingness to
set a quit date within 1 week was required for inclusion
Deﬁnition of tobacco user/smoker: self report ≥5 cpd and eCO > 7 ppm
Participants Number: 474
Average age: 45 years
Gender: 70% male
Sexuality: not directly reported, HIV risk group was ’men who have sex with men’ for
46%% and ’heterosexual contact’ for 25%
Race/ethnicity: 77% Black
cpd: 19.2 cpd
Mean FTND score: 5.73 in intervention group, 5.82 in control group
Interventions 1. Intervention: 11 counselling sessions, based on CBT, delivered via cell phone, over 3
months. Plus access to a hotline and self help written materials. Instructions to obtain
NRT patches, details of dose, frequency and duration not described. All intervention
participants also received the control interventions
2. Control: 1 brief counselling session delivered face-to-face and self help written mate-
rials. NRT as per intervention
Provider: “counsellors were trained and supervised by a licensed clinical psychologist”
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Tailoring: intervention was tailored to PLWHA through reinforcing the HIV speciﬁc
beneﬁts of abstinence. Control was not tailored
Outcomes Abstinence: 7-day PPA and continuous abstinence at 3, 6, and12months post-enrolment
Validation: eCO < 7 ppm
Notes Only PPA outcomes were included in the published report, continuous abstinence out-
comes were obtained via email communication with the authors
Funding: NCI grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...participants were randomized to 1 of 2
treatment groups”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome was assessed by self report using
a computer and eCO. Process was not de-
scribed in sufﬁcient detail to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The distribution of missing participants
was balanced between groups (retention
was 75.8% for the intervention group, and
78.2% for the control group). Missing data
imputed as missing = smoking
Selective reporting (reporting bias) Low risk The study was registered on clinicaltrials.
gov NCT00502827, all primary outcomes
were reported in full
Wewers 2000
Methods Country: US
Design: parallel “quasi-experimental” controlled trial, pilot study
Number of centres: 1
Selection: the study was advertised to clinic patients, interest in quitting smoking was
required for inclusion
Deﬁnition of tobacco user/smoker: self report ≥ 10 cpd, for ≥ 1 year
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Participants Number: 15
Average age: 40 years in intervention group, 37 years in control
Gender: 100% male
Sexuality: not reported
Race/ethnicity: not reported
cpd: 27 cpd in intervention group, 28 cpd in control
Interventions 1. Intervention: three face-to-face individual counselling sessions (duration 30 minutes)
and weekly phone calls (duration 10-15 minutes) over 8 weeks. Additional calls as
required and written materials. NRT patches 21 mg for 6 weeks
2. Control: written materials and a letter with a strong quit smoking message
Provider: peer educator (PLWHA ex-smoker) with a nurse as case manager. Peer was
“trained by a nurse in
smoking cessation treatment”
Tailoring: the intervention was tailored through use of a HIV-positive peer educator,
control was not tailored
Outcomes Abstinence: PPA and continuous abstinence at 8 weeks and 8 months post-enrolment
Validation: eCO < 8 ppm
Notes Pilot study. Poor retention of control participants, retention rate at 8 months was 43%
in control group and 88% in intervention group
Funding: National Institutes of Health, National Institute of Allergy and Infectious
Diseases, Adult AIDS Clinical Trials Group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned” but sequence genera-
tion not further described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not sufﬁciently described to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The distribution of missing participants
was unbalanced between groups, with high
loss to follow-up in the control group at 8
months. However, since no control partic-
ipants reported abstinence at 8 weeks, this
would not have effected the outcome
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Selective reporting (reporting bias) Low risk No study protocol was published. But all
primary outcomes were reported in full
CBT: cognitive behavioural therapy
CO: carbon monoxide
cpd: cigarettes per day
eCO: expired carbon monoxide
FTND score: Fagerström Test for Nicotine Dependence score
MI: motivational interviewing
NRT: nicotine replacement therapy
PPA: point prevalence smoking abstinence
ppm: parts per million
PLWHA: people living with HIV/AIDS
RCT: randomised controlled trial
TQD: target quit date
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berg 2014 Design: observational
Browning 2013 Design: review, not primary research
Burkhalter 2013 Outcome: not abstinence
Cheﬁtz 2014 Outcome: not abstinence
Cui 2012 No control group
Cummins 2005 No control group
Fuster 2009 No control group
Huber 2012 Study design: observational
Lazev 2004 Follow-up: under 30 days
Lima 2009 No control group
Matthews 2013 No control group
McKie 1985 Not primary research
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Mercie 2014 Study complete but unpublished. Author contacted, results not available
NCT01393301 Study complete but unpublished. Author contacted, results not available
NCT01436136 Multifactorial intervention. Primary outcome: not abstinence
NCT02029612 Study withdrawn
Pedrol-Clotet 2006 No control group
Reynolds 2009 Not primary research
Shadel 2014 Outcome: not abstinence
Shelley 2014 Outcome: not abstinence
Tornero 2009 No control group
Zwiebel 2008 Design: observational service review
Characteristics of ongoing studies [ordered by study ID]
NCT00701896
Trial name or title Smoking cessation using motivational therapy and varenicline
Methods Open-label, non-randomised study
Participants HIV-negative smokers and non-smokers, and HIV-positive smokers, in Ohio, US
Interventions ’Healthy control’HIV-negative non-smokers (no intervention) versus ’Healthy control’HIV-negative smokers
(no intervention) versus ’Active comparator’ HIV-positive smokers (varenicline, NRT) versus HIV-positive
smokers (one motivational interview session)
Outcomes “Develop and evaluate a specialized smoking cessation intervention” (outcome measure for evaluation not
clearly documented)
Lung function decline, the prevalence of respiratory symptoms and the occurrence/progression of emphysema
Starting date June 2008
Contact information Philip T. Diaz, Ohio State University
Notes
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NCT01363245
Trial name or title Effectiveness of smoking-cessation interventions for urban hospital patients
Methods Single-blind (outcome assessment) RCT
Participants Hospitalised HIV-positive and HIV-negative adults in New York, US. Current smokers (smoked tobacco in
last 30 days)
Interventions Hospital telephone counselling versus faxed referral to Quitline
Outcomes Abstinence at 6 and 12 months post-discharge, biochemically veriﬁed. Comparison of cessation outcomes
between HIV-positive and HIV-negative participants
Starting date July 2011
Contact information Scott E. Sherman, NYU School of Medicine
Notes
NCT01484340
Trial name or title A smoking cessation trial in HIV-infected patients in South Africa
Methods Open-label RCT
Participants HIV-positive, current daily smokers (positive SmokeScreen test) in South Africa. Willing to set a quit date
Interventions Intensive counselling versus intensive counselling + NRT
Outcomes Abstinence at 2, 6, and 12 months. Biochemically veriﬁed by eCO < 8 ppm and urine cotinine
Starting date March 2014
Contact information Sandy Chon, schon2@jhmi.edu
Notes
NCT01710137
Trial name or title A placebo controlled trial of varenicline for smoking among those with HIV/AIDS
Methods Placebo controlled, double-blind, RCT
Participants HIV-positive adults in Pennsylvania, USA. Current smokers (average at least 5 cigarettes per day)
Interventions Varenicline + smoking cessation counselling versus placebo + smoking cessation counselling
Outcomes Abstinence at 12 and 24 weeks, biochemically veriﬁed by urine cotinine
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Starting date October 2012
Contact information Sonja Blazekovic, sonjab@mail.med.upenn.edu
Notes
NCT01800019
Trial name or title The Canadian HIV Quit Smoking Trial: tackling the co-morbidities of depression and cardiovascular disease
in HIV+ smokers (CANQUIT)
Methods Four-group RCT
Participants HIV-positive, adults in Ontario, Canada. Current smokers (more than 5 cigarettes per day) and on anti-
retroviral therapy with an undetectable HIV viral load
Interventions NRT alone versus NRT and HIV tailored quit smoking counseling versus varenicline alone versus varenicline
and HIV tailored quit smoking counseling
Outcomes Abstinence at 48 weeks, biochemically veriﬁed by eCO < 10 ppm
Starting date January 2014
Contact information Louise Balfour, PhD. Ottawa Hospital Research Institute
Notes
NCT01886924
Trial name or title Computer-based MI to engage smokers living with HIV in tobacco quitline treatment
Methods 1) A pilot study to develop computer-based intervention; interviews
2) Preliminary RCT
Participants HIV-positive, adults in Rhode Island, US. Current smokers (at least 10 cigarettes per day)
Interventions Brief computer MI intervention to motivate tobacco quitline use versus computer-delivered nutrition edu-
cation (control)
Outcomes Outcomes of pilot study: feasibility and acceptability
Outcomes of RCT:engagement in cessation treatment, number of quit attempts, PPA at 6 months
Starting date February 2014
Contact information Jacki Hecht, jhecht@butler.org
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Notes
NCT01965405
Trial name or title Behavioral smoking cessation treatment for people living with HIV/AIDS
Methods Open-label RCT
Participants HIV-positive adult in Michigan, USA. Current smoker (more than 10 cigarettes per day)
Interventions Phase 1: Brief counselling + bupropion versus brief counselling + buproprion + prize contingency man-
agement. Phase 2 a: allocation dependent on non-response in phase 1. Bupropion, continued counselling,
monitored support to quit smoking versus bupropion, monitored support to quit smoking, prize contingency
management for abstinence. Phase 2 b: allocation dependent on response in Phase 1. No additional treatment
versus bupropion, continued monitoring and low intensity prize contingency management
Outcomes Abstinence at 6 and 12 months, biochemically veriﬁed by urine cotinine and eCO
Starting date August 2013
Contact information Lisa Sulkowski, lsulkows@med.wayne.edu
Notes
NCT02072772
Trial name or title A trial of Positively Smoke Free group therapy for HIV-infected smokers
Methods Open-label RCT
Participants HIV-positive adult at one of two clinics in District of Columbia and New York, US. Current smoker and
motivated to quit
Interventions Positively Smoke Free (eight group therapy sessions led by a professional and a peer) + three months NRT
versus standard care (brief advice and self help brochure) + three months NRT
Outcomes Abstinence at 6 months, biochemically veriﬁed
Starting date May 2014
Contact information Jonathan Shuter, jshuter@monteﬁore.org
Notes Linked to Moadel 2012 NCT01106638
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NCT02190643
Trial name or title Improving nicotine patch adherence among Latino HIV-positive smokers
Methods RCT
Participants HIV-positive, Latino smokers in US. Ready to set quit date
Interventions Standard care: brief counselling + eight weeks NRT versus includes a module focused on brief counselling
including a module focused on improving adherence + eight weeks NRT
Outcomes Abstinence at 3 months biochemically veriﬁed
Starting date August 2014
Contact information Joan Tucker, jtucker@rand.org
Notes
NCT02302859
Trial name or title Mobile Media-Rich Interactive Guideline System (MMRIGS) pilot study
Methods Open-label RCT
Participants HIV-positive patients at one clinic in Texas, US. Smokers (at least 5 per day and at least 100 lifetime cigarettes)
. Willing to make quit attempt within 1 week
Interventions Standard care (brief advice, 8 sessions telephone counselling + 8 weeks NRT) versus automated treatment
(brief advice + tailored video clips + 8 weeks of interactive text and graphical message via smartphone + 8
weeks NRT)
Outcomes Abstinence at 3 months, biochemically veriﬁed by urine cotinine
Starting date January 2015
Contact information Alex Prokhorov, M.D. Anderson Cancer Center
Notes
NCT02432482
Trial name or title A mobile intervention to promote cessation in HIV-infected smokers
Methods Open-label RCT
Participants HIV-positive adults at one clinic in New York, US. Current smokers who are interested in quitting and own
a smartphone
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NCT02432482 (Continued)
Interventions Standard care: brief advice, written materials and offer of NRT versus mobile Positively Smoke Free (mPSF)
providing 8 weekly sessions of audio/video messages, daily text messages + offer or NRT
Outcomes Abstinence at 3 months, biochemically veriﬁed by eCO
Starting date August 2015
Contact information Jonathan Shuter, jshuter@monteﬁore.org
Notes Linked to Shuter 2014 NCT01570595
NCT02460900
Trial name or title Optimizing smoking cessation for people with HIV/AIDS who smoke
Methods Double-blind, randomised placebo controlled trial
Participants HIV-positive adults in US
Interventions Varenicline + standard behavioural care versus placebo + standard behavioural care versus varenicline + Pos-
itively Smoke Free; tailored behavioural intervention versus placebo + Positively Smoke Free; tailored be-
havioural intervention
Outcomes Abstinence at 24 weeks
Starting date December 2015
Contact information Seth S Himelhoch, shimelho@psych.umaryland.edu
Notes
eCO: expired carbon monoxide
MI: motivational interviewing
NRT: nicotine replacement therapy
ppm: parts per million
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Tobacco cessation intervention versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Long-term abstinence (≥ 6
months)
6 1602 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.72, 1.39]
Comparison 2. Tobacco cessation intervention versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term abstinence (4 weeks
to < 6 months)
11 1785 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.15, 2.00]
Comparison 3. Subgroup by drug
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cessation at long-term follow-up 6 1602 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.72, 1.39]
1.1 NRT 5 1444 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.73, 1.42]
1.2 Varenicline 1 158 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.13, 4.38]
2 Cessation at short-term
follow-up
11 1785 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.15, 2.00]
2.1 NRT 10 1627 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.13, 1.99]
2.2 Varenicline 1 158 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.49, 5.92]
Comparison 4. Subgroup by control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Long-term cessation 6 1602 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.72, 1.39]
1.1 Standard care 4 856 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.61, 1.51]
1.2 Enhanced standard care 2 746 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.65, 1.69]
2 Short-term cessation 11 1785 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.15, 2.00]
2.1 No input 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Standard care 9 1301 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.21, 2.30]
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2.3 Enhanced standard care 1 444 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.62, 1.95]
Comparison 5. Subgroup by provider
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cessation at long-term follow-up 6 1423 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.69, 1.41]
1.1 Health care professional 5 1408 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.64, 1.33]
1.2 Researcher 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Co-facilitated by peer and
professional
1 15 Risk Ratio (M-H, Fixed, 95% CI) 8.0 [0.51, 126.67]
2 Cessation at short-term
follow-up
10 1470 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [1.19, 2.23]
2.1 Healthcare professional 6 1176 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.98, 2.03]
2.2 Researcher 2 134 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [0.72, 9.04]
2.3 Co-facilitated by peer and
professional
2 160 Risk Ratio (M-H, Fixed, 95% CI) 2.52 [1.14, 5.56]
Comparison 6. Subgroup by mode of contact
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cessation at long-term follow-up 6 1602 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.72, 1.39]
1.1 Face-to-face 2 554 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.63, 1.65]
1.2 Telephone 2 552 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.33, 1.50]
1.3 Computer 1 99 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.47, 2.62]
1.4 Text message 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.09, 10.14]
1.5 Equal face-to-face and
telephone
2 317 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.61, 2.82]
2 Cessation at short-term
follow-up
11 1785 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.15, 2.00]
2.1 Face-to-face 6 809 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.77, 1.61]
2.2 Telephone 3 646 Risk Ratio (M-H, Fixed, 95% CI) 3.69 [1.80, 7.53]
2.3 Computer 2 235 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.68, 2.34]
2.4 Text message 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.07, 3.23]
2.5 Equal face-to-face and
telephone
1 15 Risk Ratio (M-H, Fixed, 95% CI) 9.78 [0.64, 150.51]
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Comparison 7. Subgroup by selection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cessation at long-term follow-up 6 1602 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.72, 1.39]
1.1 Selected for
motivation/willingness to quit
3 647 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.49, 1.84]
1.2 Motivation/willingness to
quit not required for inclusion
3 955 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.70, 1.49]
2 Cessation at short-term
follow-up
11 1785 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.15, 2.00]
2.1 Selected for
motivation/willingness to quit
7 1052 Risk Ratio (M-H, Fixed, 95% CI) 2.74 [1.73, 4.34]
2.2 Motivation/willingness to
quit not required for inclusion
4 733 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.65, 1.35]
Comparison 8. Subgroup by tailoring
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cessation at long-term follow-up 6 1602 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.68, 1.31]
1.1 Tailored intervention
versus generic control
5 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.68, 1.33]
1.2 Tailored intervention
versus tailored control
1 158 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.13, 4.38]
1.3 Generic intervention
versus generic control
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Cessation at short-term
follow-up
11 1785 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.10, 1.91]
2.1 Tailored intervention
versus generic control
7 1463 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.02, 1.83]
2.2 Tailored intervention
versus tailored control
2 252 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [0.86, 5.01]
2.3 Generic intervention
versus generic control
2 70 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
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Comparison 9. Subgroup by number of sessions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cessation at long-term follow-up 6 1602 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.72, 1.39]
1.1 0 sessions 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.09, 10.14]
1.2 1 session 1 99 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.47, 2.62]
1.3 4 - 8 sessions 4 934 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.65, 1.50]
1.4 > 8 sessions 2 489 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.48, 2.01]
Comparison 10. Subgroup by total contact time
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cessation at long-term follow-up 5 1128 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.75, 1.55]
1.1 0 minutes 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.09, 10.14]
1.2 1 - 30 minutes 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 31 - 90 minutes 1 99 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.47, 2.62]
1.4 91 - 300 minutes 4 839 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.73, 1.80]
1.5 > 300 minutes 1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.35, 2.06]
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Analysis 1.1. Comparison 1 Tobacco cessation intervention versus control, Outcome 1 Long-term
abstinence (≥ 6 months).
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 1 Tobacco cessation intervention versus control
Outcome: 1 Long-term abstinence (≥ 6 months)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wewers 2000 4/8 0/7 0.8 % 8.00 [ 0.51, 126.67 ]
Shelley 2015 (1) 1/51 1/27 2.0 % 0.53 [ 0.03, 8.14 ]
Shelley 2015 (2) 2/54 1/26 2.1 % 0.96 [ 0.09, 10.14 ]
Humﬂeet 2013 (3) 11/58 7/41 12.7 % 1.11 [ 0.47, 2.62 ]
Humﬂeet 2013 (4) 10/69 7/41 13.6 % 0.85 [ 0.35, 2.06 ]
Stanton 2015 10/154 10/148 15.8 % 0.96 [ 0.41, 2.24 ]
Vidrine 2012 10/236 14/238 21.7 % 0.72 [ 0.33, 1.59 ]
Lloyd-Richardson 2009 21/212 21/232 31.2 % 1.09 [ 0.62, 1.95 ]
Total (95% CI) 842 760 100.0 % 1.00 [ 0.72, 1.39 ]
Total events: 69 (Intervention), 61 (Control)
Heterogeneity: Chi2 = 3.34, df = 7 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours intervention
(1) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(2) Text messages versus Control (Control arm split between interventions to avoid double counting)
(3) CBI versus Control (Control arm split between interventions to avoid double counting)
(4) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
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Analysis 2.1. Comparison 2 Tobacco cessation intervention versus control, Outcome 1 Short-term
abstinence (4 weeks to < 6 months).
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 2 Tobacco cessation intervention versus control
Outcome: 1 Short-term abstinence (4 weeks to < 6 months)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cropsey 2013 0/23 0/17 Not estimable
Humﬂeet 2013 (1) 14/69 9/41 15.5 % 0.92 [ 0.44, 1.94 ]
Humﬂeet 2013 (2) 14/58 10/41 16.1 % 0.99 [ 0.49, 2.01 ]
Ingersoll 2009 3/22 6/18 9.1 % 0.41 [ 0.12, 1.41 ]
Lloyd-Richardson 2009 21/212 21/232 27.6 % 1.09 [ 0.62, 1.95 ]
Manuel 2013 1/15 0/15 0.7 % 3.00 [ 0.13, 68.26 ]
Moadel 2012 14/73 7/72 9.7 % 1.97 [ 0.85, 4.60 ]
Shelley 2015 (3) 8/51 1/27 1.8 % 4.24 [ 0.56, 32.11 ]
Shelley 2015 (4) 2/54 2/26 3.7 % 0.48 [ 0.07, 3.23 ]
Shuter 2014 7/68 3/68 4.1 % 2.33 [ 0.63, 8.65 ]
Vidrine 2006 8/48 3/46 4.2 % 2.56 [ 0.72, 9.04 ]
Vidrine 2012 21/236 5/238 6.8 % 4.24 [ 1.62, 11.05 ]
Wewers 2000 5/8 0/7 0.7 % 9.78 [ 0.64, 150.51 ]
Total (95% CI) 937 848 100.0 % 1.51 [ 1.15, 2.00 ]
Total events: 118 (Intervention), 67 (Control)
Heterogeneity: Chi2 = 18.82, df = 11 (P = 0.06); I2 =42%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours control Favours intervention
(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) CBI versus Control (Control arm split between interventions to avoid double counting)
(3) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(4) Text messages versus Control (Control arm split between interventions to avoid double counting)
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Analysis 3.1. Comparison 3 Subgroup by drug, Outcome 1 Cessation at long-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 3 Subgroup by drug
Outcome: 1 Cessation at long-term follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NRT
Humﬂeet 2013 (1) 11/58 7/41 12.7 % 1.11 [ 0.47, 2.62 ]
Humﬂeet 2013 (2) 10/69 7/41 13.6 % 0.85 [ 0.35, 2.06 ]
Lloyd-Richardson 2009 21/212 21/232 31.2 % 1.09 [ 0.62, 1.95 ]
Stanton 2015 10/154 10/148 15.8 % 0.96 [ 0.41, 2.24 ]
Vidrine 2012 10/236 14/238 21.7 % 0.72 [ 0.33, 1.59 ]
Wewers 2000 4/8 0/7 0.8 % 8.00 [ 0.51, 126.67 ]
Subtotal (95% CI) 737 707 95.9 % 1.01 [ 0.73, 1.42 ]
Total events: 66 (Experimental), 59 (Control)
Heterogeneity: Chi2 = 3.15, df = 5 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
2 Varenicline
Shelley 2015 (3) 2/54 1/26 2.1 % 0.96 [ 0.09, 10.14 ]
Shelley 2015 (4) 1/51 1/27 2.0 % 0.53 [ 0.03, 8.14 ]
Subtotal (95% CI) 105 53 4.1 % 0.75 [ 0.13, 4.38 ]
Total events: 3 (Experimental), 2 (Control)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 842 760 100.0 % 1.00 [ 0.72, 1.39 ]
Total events: 69 (Experimental), 61 (Control)
Heterogeneity: Chi2 = 3.34, df = 7 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.01 0.1 1 10 100
Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) CBI versus Control (Control arm split between interventions to avoid double counting)
(2) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(3) Text messages versus Control (Control arm split between interventions to avoid double counting)
(4) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
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Analysis 3.2. Comparison 3 Subgroup by drug, Outcome 2 Cessation at short-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 3 Subgroup by drug
Outcome: 2 Cessation at short-term follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NRT
Cropsey 2013 0/23 0/17 Not estimable
Humﬂeet 2013 (1) 14/69 9/41 15.5 % 0.92 [ 0.44, 1.94 ]
Humﬂeet 2013 (2) 14/58 10/41 16.1 % 0.99 [ 0.49, 2.01 ]
Ingersoll 2009 3/22 6/18 9.1 % 0.41 [ 0.12, 1.41 ]
Lloyd-Richardson 2009 21/212 21/232 27.6 % 1.09 [ 0.62, 1.95 ]
Manuel 2013 1/15 0/15 0.7 % 3.00 [ 0.13, 68.26 ]
Moadel 2012 14/73 7/72 9.7 % 1.97 [ 0.85, 4.60 ]
Shuter 2014 7/68 3/68 4.1 % 2.33 [ 0.63, 8.65 ]
Vidrine 2006 8/48 3/46 4.2 % 2.56 [ 0.72, 9.04 ]
Vidrine 2012 21/236 5/238 6.8 % 4.24 [ 1.62, 11.05 ]
Wewers 2000 5/8 0/7 0.7 % 9.78 [ 0.64, 150.51 ]
Subtotal (95% CI) 832 795 94.5 % 1.50 [ 1.13, 1.99 ]
Total events: 108 (Experimental), 64 (Control)
Heterogeneity: Chi2 = 16.37, df = 9 (P = 0.06); I2 =45%
Test for overall effect: Z = 2.79 (P = 0.0052)
2 Varenicline
Shelley 2015 (3) 2/54 2/26 3.7 % 0.48 [ 0.07, 3.23 ]
Shelley 2015 (4) 8/51 1/27 1.8 % 4.24 [ 0.56, 32.11 ]
Subtotal (95% CI) 105 53 5.5 % 1.71 [ 0.49, 5.92 ]
Total events: 10 (Experimental), 3 (Control)
Heterogeneity: Chi2 = 2.47, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 937 848 100.0 % 1.51 [ 1.15, 2.00 ]
Total events: 118 (Experimental), 67 (Control)
Heterogeneity: Chi2 = 18.82, df = 11 (P = 0.06); I2 =42%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.01 0.1 1 10 100
Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) CBI versus Control (Control arm split between interventions to avoid double counting)
(3) Text messages versus Control (Control arm split between interventions to avoid double counting)
(4) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
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Analysis 4.1. Comparison 4 Subgroup by control, Outcome 1 Long-term cessation.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 4 Subgroup by control
Outcome: 1 Long-term cessation
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Standard care
Humﬂeet 2013 (1) 10/69 7/41 13.6 % 0.85 [ 0.35, 2.06 ]
Humﬂeet 2013 (2) 11/58 7/41 12.7 % 1.11 [ 0.47, 2.62 ]
Shelley 2015 (3) 1/51 1/27 2.0 % 0.53 [ 0.03, 8.14 ]
Shelley 2015 (4) 2/54 1/26 2.1 % 0.96 [ 0.09, 10.14 ]
Vidrine 2012 10/236 14/238 21.7 % 0.72 [ 0.33, 1.59 ]
Wewers 2000 4/8 0/7 0.8 % 8.00 [ 0.51, 126.67 ]
Subtotal (95% CI) 476 380 53.0 % 0.96 [ 0.61, 1.51 ]
Total events: 38 (Experimental), 30 (Control)
Heterogeneity: Chi2 = 3.14, df = 5 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
2 Enhanced standard care
Lloyd-Richardson 2009 21/212 21/232 31.2 % 1.09 [ 0.62, 1.95 ]
Stanton 2015 10/154 10/148 15.8 % 0.96 [ 0.41, 2.24 ]
Subtotal (95% CI) 366 380 47.0 % 1.05 [ 0.65, 1.69 ]
Total events: 31 (Experimental), 31 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 842 760 100.0 % 1.00 [ 0.72, 1.39 ]
Total events: 69 (Experimental), 61 (Control)
Heterogeneity: Chi2 = 3.34, df = 7 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
0.01 0.1 1 10 100
Favours combined pharmacotherapy and more intensive behavioural support Favours control
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(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) CBI versus Control (Control arm split between interventions to avoid double counting)
(3) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(4) Text messages versus Control (Control arm split between interventions to avoid double counting)
Analysis 4.2. Comparison 4 Subgroup by control, Outcome 2 Short-term cessation.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 4 Subgroup by control
Outcome: 2 Short-term cessation
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No input
Cropsey 2013 0/23 0/17 Not estimable
Subtotal (95% CI) 23 17 Not estimable
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Standard care
Humﬂeet 2013 (1) 14/69 9/41 15.5 % 0.92 [ 0.44, 1.94 ]
Humﬂeet 2013 (2) 14/58 10/41 16.1 % 0.99 [ 0.49, 2.01 ]
Ingersoll 2009 3/22 6/18 9.1 % 0.41 [ 0.12, 1.41 ]
Manuel 2013 1/15 0/15 0.7 % 3.00 [ 0.13, 68.26 ]
Moadel 2012 14/73 7/72 9.7 % 1.97 [ 0.85, 4.60 ]
Shelley 2015 (3) 8/51 1/27 1.8 % 4.24 [ 0.56, 32.11 ]
Shelley 2015 (4) 2/54 2/26 3.7 % 0.48 [ 0.07, 3.23 ]
Shuter 2014 7/68 3/68 4.1 % 2.33 [ 0.63, 8.65 ]
Vidrine 2006 8/48 3/46 4.2 % 2.56 [ 0.72, 9.04 ]
Vidrine 2012 21/236 5/238 6.8 % 4.24 [ 1.62, 11.05 ]
Wewers 2000 5/8 0/7 0.7 % 9.78 [ 0.64, 150.51 ]
Subtotal (95% CI) 702 599 72.4 % 1.67 [ 1.21, 2.30 ]
Total events: 97 (Experimental), 46 (Control)
Heterogeneity: Chi2 = 18.15, df = 10 (P = 0.05); I2 =45%
0.01 0.1 1 10 100
Favours combined pharmacotherapy and more intensive behavioural support Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 3.15 (P = 0.0016)
3 Enhanced standard care
Lloyd-Richardson 2009 21/212 21/232 27.6 % 1.09 [ 0.62, 1.95 ]
Subtotal (95% CI) 212 232 27.6 % 1.09 [ 0.62, 1.95 ]
Total events: 21 (Experimental), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 937 848 100.0 % 1.51 [ 1.15, 2.00 ]
Total events: 118 (Experimental), 67 (Control)
Heterogeneity: Chi2 = 18.82, df = 11 (P = 0.06); I2 =42%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 1.59, df = 1 (P = 0.21), I2 =37%
0.01 0.1 1 10 100
Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) CBI versus Control (Control arm split between interventions to avoid double counting)
(3) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(4) Text messages versus Control (Control arm split between interventions to avoid double counting)
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Analysis 5.1. Comparison 5 Subgroup by provider, Outcome 1 Cessation at long-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 5 Subgroup by provider
Outcome: 1 Cessation at long-term follow-up
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Health care professional
Humﬂeet 2013 (1) 10/69 7/41 16.0 % 0.85 [ 0.35, 2.06 ]
Lloyd-Richardson 2009 21/212 21/232 36.6 % 1.09 [ 0.62, 1.95 ]
Shelley 2015 (2) 1/51 1/27 2.4 % 0.53 [ 0.03, 8.14 ]
Stanton 2015 10/154 10/148 18.6 % 0.96 [ 0.41, 2.24 ]
Vidrine 2012 10/236 14/238 25.4 % 0.72 [ 0.33, 1.59 ]
Subtotal (95% CI) 722 686 99.0 % 0.92 [ 0.64, 1.33 ]
Total events: 52 (Intervention), 53 (Control)
Heterogeneity: Chi2 = 0.92, df = 4 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
2 Researcher
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Co-facilitated by peer and professional
Wewers 2000 4/8 0/7 1.0 % 8.00 [ 0.51, 126.67 ]
Subtotal (95% CI) 8 7 1.0 % 8.00 [ 0.51, 126.67 ]
Total events: 4 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Total (95% CI) 730 693 100.0 % 0.99 [ 0.69, 1.41 ]
Total events: 56 (Intervention), 53 (Control)
Heterogeneity: Chi2 = 3.25, df = 5 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 2.31, df = 1 (P = 0.13), I2 =57%
0.02 0.1 1 10 50
Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
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Analysis 5.2. Comparison 5 Subgroup by provider, Outcome 2 Cessation at short-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 5 Subgroup by provider
Outcome: 2 Cessation at short-term follow-up
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Healthcare professional
Humﬂeet 2013 (1) 14/69 9/41 20.4 % 0.92 [ 0.44, 1.94 ]
Ingersoll 2009 3/22 6/18 11.9 % 0.41 [ 0.12, 1.41 ]
Lloyd-Richardson 2009 21/212 21/232 36.2 % 1.09 [ 0.62, 1.95 ]
Manuel 2013 1/15 0/15 0.9 % 3.00 [ 0.13, 68.26 ]
Shelley 2015 (2) 8/51 1/27 2.4 % 4.24 [ 0.56, 32.11 ]
Vidrine 2012 21/236 5/238 9.0 % 4.24 [ 1.62, 11.05 ]
Subtotal (95% CI) 605 571 80.8 % 1.41 [ 0.98, 2.03 ]
Total events: 68 (Intervention), 42 (Control)
Heterogeneity: Chi2 = 12.25, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 1.87 (P = 0.062)
2 Researcher
Cropsey 2013 0/23 0/17 Not estimable
Vidrine 2006 8/48 3/46 5.5 % 2.56 [ 0.72, 9.04 ]
Subtotal (95% CI) 71 63 5.5 % 2.56 [ 0.72, 9.04 ]
Total events: 8 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
3 Co-facilitated by peer and professional
Moadel 2012 14/73 7/72 12.7 % 1.97 [ 0.85, 4.60 ]
Wewers 2000 5/8 0/7 1.0 % 9.78 [ 0.64, 150.51 ]
Subtotal (95% CI) 81 79 13.7 % 2.52 [ 1.14, 5.56 ]
Total events: 19 (Intervention), 7 (Control)
Heterogeneity: Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 2.28 (P = 0.022)
Total (95% CI) 757 713 100.0 % 1.63 [ 1.19, 2.23 ]
Total events: 95 (Intervention), 52 (Control)
Heterogeneity: Chi2 = 16.00, df = 8 (P = 0.04); I2 =50%
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Chi2 = 2.23, df = 2 (P = 0.33), I2 =10%
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Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
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Analysis 6.1. Comparison 6 Subgroup by mode of contact, Outcome 1 Cessation at long-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 6 Subgroup by mode of contact
Outcome: 1 Cessation at long-term follow-up
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Face-to-face
Humﬂeet 2013 (1) 10/69 7/41 13.6 % 0.85 [ 0.35, 2.06 ]
Lloyd-Richardson 2009 21/212 21/232 31.2 % 1.09 [ 0.62, 1.95 ]
Subtotal (95% CI) 281 273 44.8 % 1.02 [ 0.63, 1.65 ]
Total events: 31 (Intervention), 28 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
2 Telephone
Shelley 2015 (2) 1/51 1/27 2.0 % 0.53 [ 0.03, 8.14 ]
Vidrine 2012 10/236 14/238 21.7 % 0.72 [ 0.33, 1.59 ]
Subtotal (95% CI) 287 265 23.7 % 0.70 [ 0.33, 1.50 ]
Total events: 11 (Intervention), 15 (Control)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
3 Computer
Humﬂeet 2013 (3) 11/58 7/41 12.7 % 1.11 [ 0.47, 2.62 ]
Subtotal (95% CI) 58 41 12.7 % 1.11 [ 0.47, 2.62 ]
Total events: 11 (Intervention), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
4 Text message
Shelley 2015 (4) 2/54 1/26 2.1 % 0.96 [ 0.09, 10.14 ]
Subtotal (95% CI) 54 26 2.1 % 0.96 [ 0.09, 10.14 ]
Total events: 2 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
5 Equal face-to-face and telephone
Stanton 2015 10/154 10/148 15.8 % 0.96 [ 0.41, 2.24 ]
Wewers 2000 4/8 0/7 0.8 % 8.00 [ 0.51, 126.67 ]
Subtotal (95% CI) 162 155 16.7 % 1.31 [ 0.61, 2.82 ]
Total events: 14 (Intervention), 10 (Control)
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 2.16, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 842 760 100.0 % 1.00 [ 0.72, 1.39 ]
Total events: 69 (Intervention), 61 (Control)
Heterogeneity: Chi2 = 3.34, df = 7 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 1.35, df = 4 (P = 0.85), I2 =0.0%
0.005 0.1 1 10 200
Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(3) CBI versus Control (Control arm split between interventions to avoid double counting)
(4) Text messages versus Control (Control arm split between interventions to avoid double counting)
Analysis 6.2. Comparison 6 Subgroup by mode of contact, Outcome 2 Cessation at short-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 6 Subgroup by mode of contact
Outcome: 2 Cessation at short-term follow-up
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Face-to-face
Cropsey 2013 0/23 0/17 Not estimable
Humﬂeet 2013 (1) 14/69 9/41 15.5 % 0.92 [ 0.44, 1.94 ]
Ingersoll 2009 3/22 6/18 9.1 % 0.41 [ 0.12, 1.41 ]
Lloyd-Richardson 2009 21/212 21/232 27.6 % 1.09 [ 0.62, 1.95 ]
Manuel 2013 1/15 0/15 0.7 % 3.00 [ 0.13, 68.26 ]
Moadel 2012 14/73 7/72 9.7 % 1.97 [ 0.85, 4.60 ]
Subtotal (95% CI) 414 395 62.5 % 1.11 [ 0.77, 1.61 ]
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Favours combined pharmacotherapy and more intensive behavioural support Favours control
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 53 (Intervention), 43 (Control)
Heterogeneity: Chi2 = 4.89, df = 4 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Telephone
Shelley 2015 (2) 8/51 1/27 1.8 % 4.24 [ 0.56, 32.11 ]
Vidrine 2006 8/48 3/46 4.2 % 2.56 [ 0.72, 9.04 ]
Vidrine 2012 21/236 5/238 6.8 % 4.24 [ 1.62, 11.05 ]
Subtotal (95% CI) 335 311 12.8 % 3.69 [ 1.80, 7.53 ]
Total events: 37 (Intervention), 9 (Control)
Heterogeneity: Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 3.58 (P = 0.00035)
3 Computer
Humﬂeet 2013 (3) 14/58 10/41 16.1 % 0.99 [ 0.49, 2.01 ]
Shuter 2014 7/68 3/68 4.1 % 2.33 [ 0.63, 8.65 ]
Subtotal (95% CI) 126 109 20.2 % 1.26 [ 0.68, 2.34 ]
Total events: 21 (Intervention), 13 (Control)
Heterogeneity: Chi2 = 1.30, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.74 (P = 0.46)
4 Text message
Shelley 2015 (4) 2/54 2/26 3.7 % 0.48 [ 0.07, 3.23 ]
Subtotal (95% CI) 54 26 3.7 % 0.48 [ 0.07, 3.23 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
5 Equal face-to-face and telephone
Wewers 2000 5/8 0/7 0.7 % 9.78 [ 0.64, 150.51 ]
Subtotal (95% CI) 8 7 0.7 % 9.78 [ 0.64, 150.51 ]
Total events: 5 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Total (95% CI) 937 848 100.0 % 1.51 [ 1.15, 2.00 ]
Total events: 118 (Intervention), 67 (Control)
Heterogeneity: Chi2 = 18.82, df = 11 (P = 0.06); I2 =42%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 11.81, df = 4 (P = 0.02), I2 =66%
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Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(3) CBI versus Control (Control arm split between interventions to avoid double counting)
(4) Text messages versus Control (Control arm split between interventions to avoid double counting)
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Analysis 7.1. Comparison 7 Subgroup by selection, Outcome 1 Cessation at long-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 7 Subgroup by selection
Outcome: 1 Cessation at long-term follow-up
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Selected for motivation/willingness to quit
Shelley 2015 (1) 1/51 1/27 2.0 % 0.53 [ 0.03, 8.14 ]
Shelley 2015 (2) 2/54 1/26 2.1 % 0.96 [ 0.09, 10.14 ]
Vidrine 2012 10/236 14/238 21.7 % 0.72 [ 0.33, 1.59 ]
Wewers 2000 4/8 0/7 0.8 % 8.00 [ 0.51, 126.67 ]
Subtotal (95% CI) 349 298 26.6 % 0.95 [ 0.49, 1.84 ]
Total events: 17 (Intervention), 16 (Control)
Heterogeneity: Chi2 = 2.93, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Motivation/willingness to quit not required for inclusion
Humﬂeet 2013 (3) 10/69 7/41 13.6 % 0.85 [ 0.35, 2.06 ]
Humﬂeet 2013 (4) 11/58 7/41 12.7 % 1.11 [ 0.47, 2.62 ]
Lloyd-Richardson 2009 21/212 21/232 31.2 % 1.09 [ 0.62, 1.95 ]
Stanton 2015 10/154 10/148 15.8 % 0.96 [ 0.41, 2.24 ]
Subtotal (95% CI) 493 462 73.4 % 1.02 [ 0.70, 1.49 ]
Total events: 52 (Intervention), 45 (Control)
Heterogeneity: Chi2 = 0.28, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Total (95% CI) 842 760 100.0 % 1.00 [ 0.72, 1.39 ]
Total events: 69 (Intervention), 61 (Control)
Heterogeneity: Chi2 = 3.34, df = 7 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(2) Text messages versus Control (Control arm split between interventions to avoid double counting)
(3) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(4) CBI versus Control (Control arm split between interventions to avoid double counting)
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Analysis 7.2. Comparison 7 Subgroup by selection, Outcome 2 Cessation at short-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 7 Subgroup by selection
Outcome: 2 Cessation at short-term follow-up
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Selected for motivation/willingness to quit
Manuel 2013 1/15 0/15 0.7 % 3.00 [ 0.13, 68.26 ]
Moadel 2012 14/73 7/72 9.7 % 1.97 [ 0.85, 4.60 ]
Shelley 2015 (1) 8/51 1/27 1.8 % 4.24 [ 0.56, 32.11 ]
Shelley 2015 (2) 2/54 2/26 3.7 % 0.48 [ 0.07, 3.23 ]
Shuter 2014 7/68 3/68 4.1 % 2.33 [ 0.63, 8.65 ]
Vidrine 2006 8/48 3/46 4.2 % 2.56 [ 0.72, 9.04 ]
Vidrine 2012 21/236 5/238 6.8 % 4.24 [ 1.62, 11.05 ]
Wewers 2000 5/8 0/7 0.7 % 9.78 [ 0.64, 150.51 ]
Subtotal (95% CI) 553 499 31.8 % 2.74 [ 1.73, 4.34 ]
Total events: 66 (Intervention), 21 (Control)
Heterogeneity: Chi2 = 5.66, df = 7 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 4.28 (P = 0.000018)
2 Motivation/willingness to quit not required for inclusion
Cropsey 2013 0/23 0/17 Not estimable
Humﬂeet 2013 (3) 14/69 9/41 15.5 % 0.92 [ 0.44, 1.94 ]
Humﬂeet 2013 (4) 14/58 10/41 16.1 % 0.99 [ 0.49, 2.01 ]
Ingersoll 2009 3/22 6/18 9.1 % 0.41 [ 0.12, 1.41 ]
Lloyd-Richardson 2009 21/212 21/232 27.6 % 1.09 [ 0.62, 1.95 ]
Subtotal (95% CI) 384 349 68.2 % 0.94 [ 0.65, 1.35 ]
Total events: 52 (Intervention), 46 (Control)
Heterogeneity: Chi2 = 2.03, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 937 848 100.0 % 1.51 [ 1.15, 2.00 ]
Total events: 118 (Intervention), 67 (Control)
Heterogeneity: Chi2 = 18.82, df = 11 (P = 0.06); I2 =42%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 12.75, df = 1 (P = 0.00), I2 =92%
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(1) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(2) Text messages versus Control (Control arm split between interventions to avoid double counting)
(3) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(4) CBI versus Control (Control arm split between interventions to avoid double counting)
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Analysis 8.1. Comparison 8 Subgroup by tailoring, Outcome 1 Cessation at long-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 8 Subgroup by tailoring
Outcome: 1 Cessation at long-term follow-up
Study or subgroup Control Intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tailored intervention versus generic control
Humﬂeet 2013 (1) 10/69 7/41 13.3 % 0.85 [ 0.35, 2.06 ]
Humﬂeet 2013 (2) 11/58 7/41 12.4 % 1.11 [ 0.47, 2.62 ]
Lloyd-Richardson 2009 19/212 23/232 33.1 % 0.90 [ 0.51, 1.61 ]
Stanton 2015 10/154 10/148 15.4 % 0.96 [ 0.41, 2.24 ]
Vidrine 2012 10/236 14/238 21.0 % 0.72 [ 0.33, 1.59 ]
Wewers 2000 4/8 0/7 0.8 % 8.00 [ 0.51, 126.67 ]
Subtotal (95% CI) 737 707 96.0 % 0.95 [ 0.68, 1.33 ]
Total events: 64 (Control), 61 (Intervention)
Heterogeneity: Chi2 = 2.98, df = 5 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Tailored intervention versus tailored control
Shelley 2015 (3) 2/54 1/26 2.0 % 0.96 [ 0.09, 10.14 ]
Shelley 2015 (4) 1/51 1/27 2.0 % 0.53 [ 0.03, 8.14 ]
Subtotal (95% CI) 105 53 4.0 % 0.75 [ 0.13, 4.38 ]
Total events: 3 (Control), 2 (Intervention)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
3 Generic intervention versus generic control
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Control), 0 (Intervention)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 842 760 100.0 % 0.94 [ 0.68, 1.31 ]
Total events: 67 (Control), 63 (Intervention)
Heterogeneity: Chi2 = 3.13, df = 7 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
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(1) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(2) CBI versus Control (Control arm split between interventions to avoid double counting)
(3) Text messages versus Control (Control arm split between interventions to avoid double counting)
(4) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
Analysis 8.2. Comparison 8 Subgroup by tailoring, Outcome 2 Cessation at short-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 8 Subgroup by tailoring
Outcome: 2 Cessation at short-term follow-up
Study or subgroup Control Intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tailored intervention versus generic control
Humﬂeet 2013 (1) 14/58 10/41 15.7 % 0.99 [ 0.49, 2.01 ]
Humﬂeet 2013 (2) 14/69 9/41 15.1 % 0.92 [ 0.44, 1.94 ]
Ingersoll 2009 3/22 6/18 8.8 % 0.41 [ 0.12, 1.41 ]
Lloyd-Richardson 2009 19/212 23/232 29.4 % 0.90 [ 0.51, 1.61 ]
Moadel 2012 14/73 7/72 9.4 % 1.97 [ 0.85, 4.60 ]
Shuter 2014 7/68 3/68 4.0 % 2.33 [ 0.63, 8.65 ]
Vidrine 2012 21/236 5/238 6.7 % 4.24 [ 1.62, 11.05 ]
Wewers 2000 5/8 0/7 0.7 % 9.78 [ 0.64, 150.51 ]
Subtotal (95% CI) 746 717 89.9 % 1.37 [ 1.02, 1.83 ]
Total events: 97 (Control), 63 (Intervention)
Heterogeneity: Chi2 = 16.18, df = 7 (P = 0.02); I2 =57%
Test for overall effect: Z = 2.09 (P = 0.037)
2 Tailored intervention versus tailored control
Shelley 2015 (3) 8/51 1/27 1.8 % 4.24 [ 0.56, 32.11 ]
Shelley 2015 (4) 2/54 2/26 3.6 % 0.48 [ 0.07, 3.23 ]
Vidrine 2006 8/48 3/46 4.1 % 2.56 [ 0.72, 9.04 ]
Subtotal (95% CI) 153 99 9.5 % 2.07 [ 0.86, 5.01 ]
Total events: 18 (Control), 6 (Intervention)
Heterogeneity: Chi2 = 2.84, df = 2 (P = 0.24); I2 =30%
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(. . . Continued)
Study or subgroup Control Intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.62 (P = 0.11)
3 Generic intervention versus generic control
Cropsey 2013 0/23 0/17 Not estimable
Manuel 2013 1/15 0/15 0.7 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 38 32 0.7 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Control), 0 (Intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 937 848 100.0 % 1.44 [ 1.10, 1.91 ]
Total events: 116 (Control), 69 (Intervention)
Heterogeneity: Chi2 = 20.11, df = 11 (P = 0.04); I2 =45%
Test for overall effect: Z = 2.61 (P = 0.0092)
Test for subgroup differences: Chi2 = 0.99, df = 2 (P = 0.61), I2 =0.0%
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(1) CBI versus Control (Control arm split between interventions to avoid double counting)
(2) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(3) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(4) Text messages versus Control (Control arm split between interventions to avoid double counting)
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Analysis 9.1. Comparison 9 Subgroup by number of sessions, Outcome 1 Cessation at long-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 9 Subgroup by number of sessions
Outcome: 1 Cessation at long-term follow-up
Study or subgroup Control Intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0 sessions
Shelley 2015 (1) 2/54 1/26 2.1 % 0.96 [ 0.09, 10.14 ]
Subtotal (95% CI) 54 26 2.1 % 0.96 [ 0.09, 10.14 ]
Total events: 2 (Control), 1 (Intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
2 1 session
Humﬂeet 2013 (2) 11/58 7/41 12.7 % 1.11 [ 0.47, 2.62 ]
Subtotal (95% CI) 58 41 12.7 % 1.11 [ 0.47, 2.62 ]
Total events: 11 (Control), 7 (Intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 4 - 8 sessions
Humﬂeet 2013 (3) 10/69 7/41 13.6 % 0.85 [ 0.35, 2.06 ]
Lloyd-Richardson 2009 21/212 21/232 31.2 % 1.09 [ 0.62, 1.95 ]
Shelley 2015 (4) 1/51 1/27 2.0 % 0.53 [ 0.03, 8.14 ]
Stanton 2015 10/154 10/148 15.8 % 0.96 [ 0.41, 2.24 ]
Subtotal (95% CI) 486 448 62.7 % 0.99 [ 0.65, 1.50 ]
Total events: 42 (Control), 39 (Intervention)
Heterogeneity: Chi2 = 0.44, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
4 > 8 sessions
Vidrine 2012 10/236 14/238 21.7 % 0.72 [ 0.33, 1.59 ]
Wewers 2000 4/8 0/7 0.8 % 8.00 [ 0.51, 126.67 ]
Subtotal (95% CI) 244 245 22.5 % 0.99 [ 0.48, 2.01 ]
Total events: 14 (Control), 14 (Intervention)
Heterogeneity: Chi2 = 2.81, df = 1 (P = 0.09); I2 =64%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 842 760 100.0 % 1.00 [ 0.72, 1.39 ]
Total events: 69 (Control), 61 (Intervention)
Heterogeneity: Chi2 = 3.34, df = 7 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 0.06, df = 3 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
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(1) Text messages versus Control (Control arm split between interventions to avoid double counting)
(2) CBI versus Control (Control arm split between interventions to avoid double counting)
(3) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
(4) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
Analysis 10.1. Comparison 10 Subgroup by total contact time, Outcome 1 Cessation at long-term follow-up.
Review: Interventions for tobacco use cessation in people living with HIV and AIDS
Comparison: 10 Subgroup by total contact time
Outcome: 1 Cessation at long-term follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0 minutes
Shelley 2015 (1) 2/54 1/26 2.7 % 0.96 [ 0.09, 10.14 ]
Subtotal (95% CI) 54 26 2.7 % 0.96 [ 0.09, 10.14 ]
Total events: 2 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
2 1 - 30 minutes
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 31 - 90 minutes
Humﬂeet 2013 (2) 11/58 7/41 16.3 % 1.11 [ 0.47, 2.62 ]
Subtotal (95% CI) 58 41 16.3 % 1.11 [ 0.47, 2.62 ]
Total events: 11 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
4 91 - 300 minutes
Lloyd-Richardson 2009 21/212 21/232 39.8 % 1.09 [ 0.62, 1.95 ]
Shelley 2015 (3) 1/51 1/27 2.6 % 0.53 [ 0.03, 8.14 ]
Stanton 2015 10/154 10/148 20.2 % 0.96 [ 0.41, 2.24 ]
Wewers 2000 4/8 0/7 1.0 % 8.00 [ 0.51, 126.67 ]
0.005 0.1 1 10 200
Favours combined pharmacotherapy and more intensive behavioural support Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 425 414 63.6 % 1.14 [ 0.73, 1.80 ]
Total events: 36 (Experimental), 32 (Control)
Heterogeneity: Chi2 = 2.39, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
5 > 300 minutes
Humﬂeet 2013 (4) 10/69 7/41 17.4 % 0.85 [ 0.35, 2.06 ]
Subtotal (95% CI) 69 41 17.4 % 0.85 [ 0.35, 2.06 ]
Total events: 10 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 606 522 100.0 % 1.08 [ 0.75, 1.55 ]
Total events: 59 (Experimental), 47 (Control)
Heterogeneity: Chi2 = 2.66, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.36, df = 3 (P = 0.95), I2 =0.0%
0.005 0.1 1 10 200
Favours combined pharmacotherapy and more intensive behavioural support Favours control
(1) Text messages versus Control (Control arm split between interventions to avoid double counting)
(2) CBI versus Control (Control arm split between interventions to avoid double counting)
(3) Adherence Behavioural Therapys versus Control (Control arm split between interventions to avoid double counting)
(4) Individual counselling versus Control (Control arm split between interventions to avoid double counting)
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Search terms for MEDLINE search:
1. RANDOMIZED-CONTROLLED-TRIAL.pt.
2. CONTROLLED-CLINICAL-TRIAL.pt.
3. CLINICAL-TRIAL.pt.
4. Meta analysis.pt.
5. exp Clinical Trial/
6. Random-Allocation/
7. randomized-controlled trials/
8. double-blind-method/
9. single-blind-method/
10. placebos/
11. Research-Design/
12. ((clin$ adj5 trial$) or placebo$ or random$).ti,ab.
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13. ((singl$ or doubl$ or trebl$ or tripl$) adj5 (blind$ or mask$)).ti,ab.
14. (volunteer$ or prospectiv$).ti,ab.
15. exp Follow-Up-Studies/
16. exp Retrospective-Studies/
17. exp Prospective-Studies/
18. exp Evaluation-Studies/ or Program-Evaluation.mp.
19. exp Cross-Sectional-Studies/
20. exp Behavior-therapy/
21. exp Health-Promotion/
22. exp Community-Health-Services/
23. exp Health-Education/
24. exp Health-Behavior/
25. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. smoking cessation.mp. or exp Smoking Cessation/
27. “Tobacco-Use-Cessation”/
28. “Tobacco-Use-Disorder”/
29. Tobacco-Smokeless/
30. exp Tobacco-Smoke-Pollution/
31. exp Tobacco-/
32. exp Nicotine-/
33. ((quit$ or stop$ or ceas$ or giv$) adj5 smoking).ti,ab.
34. exp Smoking/pc, th [Prevention & Control, Therapy]
35. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 [A category smoking terms]
36. exp Smoking/ not 35 [B category smoking terms]
37. 1 or 2 or 3 [Likely CT design terms; RCTs, CCTs, Clinical trials]
38. 35 and 25 [A category smoking+all design terms]
39. 35 and 37 [A category smoking terms+likely CT design terms]
40. (animals not humans).sh. [used with ’not’ to exclude animal studies for each subset]
41. ((26 or 27 or 28 or 29) and REVIEW.pt.) not 38 [Set 4: Core smoking related reviews only]
42. 36 and 25 [B category smoking+all design terms]
43. (42 and 37) not 40 [Set 3: B smoking terms, likely CT design terms, human only]
44. 38 not 39 not 40 [Set 2: A smoking terms, not core CT terms, human only]
45. (35 and 37) not 40 [Set 1: A smoking terms, likely CT design terms, human only]
46. exp Smoking Cessation/ not (44 or 45) [Smoking cessation only, no design terms]
47. exp hiv infections/ or exp acquired immunodeﬁciency syndrome/
48. hiv/ or hiv-1/ or hiv-2/
49. (“acquired immunodeﬁciency syndrome” or “acquired immunedeﬁciency syndrome” or “acquired immuno-deﬁciency syndrome”
or “acquired immune-deﬁciency syndrome”).mp.
50. “HIV/AIDS”.mp.
51. HIV.mp.
52. PLWHA.mp
53. 47 or 48 or 49 or 50 or 51 or 52 [Any topic term]
54. 45 and 53 [Set 1 plus topic]
55. 44 and 53 [Set 2 plus topic]
56. 43 and 53 [Set 3 plus topic]
57. 54 or 55 or 56 [All sets]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We could not address one of the secondary objectives - to assess whether interventions combining pharmacotherapy and behavioural
support are more effective than either type of support alone in PLWHA - due to all included studies providing a combined intervention.
We added a post hoc objective - to assess whether more intense behavioural support is more effective. This involved analysis according
to number of sessions and total duration of contact time.
Wewere unable to perform the planned synthesis of adverse events orHIVoutcomes (CD4 count, viral load or incidence of opportunistic
infections), since they were not reported in more than one study.
Two new authors (RL and PW) joined the review team following the protocol.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Acquired Immunodeﬁciency Syndrome; ∗HIV Infections; Behavior Therapy [methods]; Nicotinic Agonists [therapeutic use]; Ran-
domized Controlled Trials as Topic; Smoking Cessation [methods]; Time Factors; Tobacco Use Cessation [∗methods]; Varenicline
[therapeutic use]
MeSH check words
Humans
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